Amedeo Smart

Free Medical Literature Service

 

Amedeo

Otorhinolaryngology
  Free Subscription

Articles published in
Oral Oncol
    May 2024
  1. DHARMALINGAM JOTHINATHAN MK
    Outcomes of transoral robotic surgery for early-stage oropharyngeal squamous cell carcinoma with low rates of adjuvant therapy: A consecutive single-institution study from 2013 to 2020.
    Oral Oncol. 2024;152:106811.
    >> Share

  2. POOJARI M, Madabhavi I, Desai S
    Extraskeletal Ewing's sarcoma of supraglottis: A rare case report.
    Oral Oncol. 2024;152:106789.
    >> Share

  3. MELDGAARD JUSTESEN M, Kronberg Jakobsen K, Fenger Carlander AL, Hjordt Holm Larsen M, et al
    Outcomes of transoral robotic surgery for early-stage oropharyngeal squamous cell carcinoma with low rates of adjuvant therapy: A consecutive single-institution study from 2013 to 2020.
    Oral Oncol. 2024;152:106783.
    >> Share

    April 2024
  4. TONSBEEK AM, Hundepool CA, Roubos J, Rijken B, et al
    Quality of life in 583 head and neck cancer survivors assessed with the FACE-Q head and neck cancer module.
    Oral Oncol. 2024;153:106813.
    >> Share

  5. MICHIKAWA C, Gleber-Netto FO, Pickering CR, Rao X, et al
    Immune infiltration at the primary tumor is associated with clinical outcome of patients with extranodal extension of lymph node metastasis in oral cancer.
    Oral Oncol. 2024;153:106729.
    >> Share

  6. FANG Q, Yuan J, Zhang X, Dai L, et al
    Oncologic and functional results between sentinel lymph node biopsy and elective neck dissection in cT1/2N0 maxillary squamous cell carcinoma.
    Oral Oncol. 2024;152:106810.
    >> Share

  7. YEO BSY, Lee RS, Lim NE, Tan E, et al
    Efficacy and Safety of Cell-based Immunotherapy in The Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma - A Systematic Review and Meta-analysis.
    Oral Oncol. 2024;152:106786.
    >> Share

  8. LI Y, Zhou Y, Zhao C, Liu L, et al
    The circadian clock gene, BMAL1, promotes radiosensitization in nasopharyngeal carcinoma by inhibiting the epithelial-to-mesenchymal transition via the TGF-beta1/Smads/Snail1 axis.
    Oral Oncol. 2024;152:106798.
    >> Share

  9. RAMASAMY P, Sekaran S, Ganapathy D
    Oral cancer burden in tribal populations residing in India.
    Oral Oncol. 2024;152:106801.
    >> Share

  10. SEKAR D
    Comment on betel-nut chewing does not influence PD-L1 expression rates in recurrent/metastatic head and neck squamous cell carcinoma (HNSCC): A prospective biomarker prevalence study.
    Oral Oncol. 2024;152:106800.
    >> Share

  11. SARAVANAN M
    Comment on "Nanomedicine, an emerging therapeutic strategy for oral cancer therapy".
    Oral Oncol. 2024;152:106806.
    >> Share

  12. RICARDO ELIAS DE MELO P, Agra Monteiro M, Henrique Rocha Aragao H, Vitoria de Araujo Lopes N, et al
    Comment on "Awareness regarding oral cancer amongst the dental, medical, and nursing students: Is something lacking?".
    Oral Oncol. 2024;152:106802.
    >> Share

  13. SMITH JD, Heft-Neal ME, Rosko AJ, Chepeha DB, et al
    Upfront neck dissection to guide single-modality therapy for early stage supraglottic squamous cell carcinoma.
    Oral Oncol. 2024;152:106803.
    >> Share

  14. KONO M, Saito S, Rokugo M, Egloff AM, et al
    Enhanced oral versus flank lymph node T cell response parallels anti-PD1 efficacy in head and neck cancer.
    Oral Oncol. 2024;152:106795.
    >> Share

  15. SEGNA E, Civita F, Denaro N, Beltramini GA, et al
    Cavernous sinus metastasis in head and neck cancer: Focus on oral squamous cell cancer.
    Oral Oncol. 2024;152:106784.
    >> Share

  16. SIVAPERUMAL P, Ganapathy D, Kamala K
    Revolutionizing oral cancer treatment: Harnessing the potential of adaptive CARneg T cell therapy.
    Oral Oncol. 2024;152:106794.
    >> Share

  17. RAJAKUMAR HK, Coimbatore Sathyabal V, Vivekanandam A, Nasrin Jabarulla K, et al
    Evaluation of nuclear morphometry in exfoliative cytology of buccal mucosa in patients with high risk of oral cancer.
    Oral Oncol. 2024;152:106793.
    >> Share

  18. SARAVANAN M
    Comment on "The microbiome and oral cancer: More questions than answers".
    Oral Oncol. 2024;152:106792.
    >> Share

  19. ARAGAO HHR, Monteiro MA, Lopes NVA, Cunha JLS, et al
    Comment on "Betel-nut chewing does not influence PD-L1 expression rates in recurrent/metastatic head and neck squamous cell carcinoma (HNSCC): A prospective biomarker prevalence study".
    Oral Oncol. 2024;152:106788.
    >> Share

  20. DAS R, Misra SR, Nayak A
    Awareness regarding oral cancer amongst the dental, medical, and nursing students: Is something lacking?
    Oral Oncol. 2024;152:106790.
    >> Share

  21. XIAO X, Shi Z, Song Z
    Comment on circulatory mitochondrial DNA as a novel biomarker for head and neck cancers.
    Oral Oncol. 2024;152:106785.
    >> Share

  22. GASNE C, Atallah S, Dauzier E, Thariat J, et al
    Twelve years after: The french national network on rare head and neck tumours (REFCOR).
    Oral Oncol. 2024;151:106762.
    >> Share

  23. MALI SB
    Role of telemedicine in head neck cancer.
    Oral Oncol. 2024;151:106746.
    >> Share

  24. MIRIMOGHADDAM M, Bohlouli B, Lai H, Viegas S, et al
    Trends and predictors of unplanned hospitalization among oral and oropharyngeal cancer patients; an 8-year population-based study.
    Oral Oncol. 2024;151:106742.
    >> Share

    March 2024
  25. MEGAHED R, Prabhu AV, Mack DP, Gholami S, et al
    Re-irradiation of recurrent head and neck cancers using pulsed reduced dose rate radiotherapy: An institutional series.
    Oral Oncol. 2024;152:106778.
    >> Share

  26. LORINI L, Gili R, Salvestrini V, Morelli I, et al
    De novo metastatic head and neck squamous cell carcinoma: Why does locoregional control "always" matter?
    Oral Oncol. 2024;152:106768.
    >> Share

  27. XIROU V, Moutafi M, Bai Y, Nwe Aung T, et al
    An algorithm for standardization of tumor Infiltrating lymphocyte evaluation in head and neck cancers.
    Oral Oncol. 2024;152:106750.
    >> Share

  28. HONG RL, Yen CJ, Lien MY, Cheng R, et al
    Betel-nut chewing does not influence PD-L1 expression rates in recurrent/metastatic head and neck squamous cell carcinoma (HNSCC): A prospective biomarker prevalence study.
    Oral Oncol. 2024;152:106760.
    >> Share

  29. FERRARI M, Mularoni F, Taboni S, Crosetti E, et al
    How reliable is assessment of true vocal cord-arytenoid unit mobility in patients affected by laryngeal cancer? a multi-institutional study on 366 patients from the ARYFIX collaborative group.
    Oral Oncol. 2024;152:106744.
    >> Share

  30. TOYA R, Fukugawa Y, Saito T, Matsuyama T, et al
    Radiation Therapy Oncology Group 8502 "QUAD shot" regimen using volumetric modulated arc therapy for incurable head and neck cancer.
    Oral Oncol. 2024;151:106752.
    >> Share

  31. RUIZ-TORRES DA, Naegele S, Podury A, Wirth L, et al
    Immunotherapy time of infusion impacts survival in head and neck cancer: A propensity score matched analysis.
    Oral Oncol. 2024;151:106761.
    >> Share

  32. SIMON L, Paly J, Park E, Samuels-Kalow M, et al
    Medicare dental coverage for patients with head and neck cancer: An opportunity in need of advocates.
    Oral Oncol. 2024 Mar 15:106754. doi: 10.1016/j.oraloncology.2024.106754.
    >> Share

  33. RICARDO ELIAS DE MELO P, Agra Monteiro M, Vitoria de Araujo Lopes N, Silva Cunha JL, et al
    Comment on "advancing oral cancer diagnosis in Brazil: Integrating artificial intelligence with Teledentistry for Better Patient Outcomes".
    Oral Oncol. 2024;151:106758.
    >> Share

  34. RAJANATHADURAI J, Sindya J, Madar IH, Perumal E, et al
    Exosomal immune checkpoint protein (PD-L1): Hidden player in PD-1/PD-L1 blockade immunotherapy resistance in oral cancer.
    Oral Oncol. 2024;151:106748.
    >> Share

  35. ZUPANCIC M, Kostopoulou ON, Holzhauser S, Lukoseviciute M, et al
    Human papillomavirus (HPV) load is higher in HPVDNA/p16 positive than in HPVDNA positive/p16 negative oropharyngeal squamous cell carcinoma but does not differ significantly between various subsites or correlate to survival.
    Oral Oncol. 2024;151:106749.
    >> Share

  36. FERRARO T, Pershad AR, Arora S, Lee E, et al
    The utility of ultrasonographic surveillance in management of a presumed branchial cleft cyst later confirmed HPV-associated oropharyngeal cancer.
    Oral Oncol. 2024;151:106743.
    >> Share

  37. KIM DH, Lim ST, Kim HR, Kang EJ, et al
    Impact of PIK3CA and cell cycle pathway genetic alterations on durvalumab efficacy in patients with head and neck squamous cell carcinoma: Post hoc analysis of TRIUMPH study.
    Oral Oncol. 2024;151:106739.
    >> Share

  38. SANTANA LADM, Floresta LG, Alves EVM, Melo LMR, et al
    Advancing oral cancer diagnosis in Brazil: Integrating artificial intelligence with teledentistry for enhanced patient outcomes.
    Oral Oncol. 2024;151:106741.
    >> Share

  39. CHEN K, Shi M, Mo S, Liu T, et al
    Clinical features and prognostic factors of nasopharyngeal carcinoma with brain metastases.
    Oral Oncol. 2024;151:106738.
    >> Share

  40. DING C, Dai DY, Luo ZK, Wang GY, et al
    Evaluation of a novel model incorporating serological indicators into the conventional TNM staging system for nasopharyngeal carcinoma.
    Oral Oncol. 2024;151:106725.
    >> Share

  41. LU X, Zhang JL, Zhai X, Liu Q, et al
    A case report on a nasal and oral cavity involving large solitary fibrous tumor and comprehensive review of case literature.
    Oral Oncol. 2024;150:106715.
    >> Share

  42. YOUNG RJ, Angel C, Bressel M, Pizzolla A, et al
    Characterising B cell expression and prognostic significance in human papillomavirus positive oropharyngeal cancer.
    Oral Oncol. 2024;150:106687.
    >> Share

    February 2024
  43. VAN SCHAIK JE, van der Vegt B, Slagter-Menkema L, van der Laan BFAM, et al
    Identification of new head and neck squamous cell carcinoma molecular imaging targets.
    Oral Oncol. 2024;151:106736.
    >> Share

  44. MELACHURI M, Kurukulasuriya C, Rumde P, Patel T, et al
    Treatment package time < 14 weeks improves recurrence free and disease specific survival in HPV positive OPC with high-risk features.
    Oral Oncol. 2024;151:106703.
    >> Share

  45. AHMED AA, Sborchia M, Bye H, Roman-Escorza M, et al
    Mutation detection in saliva from oral cancer patients.
    Oral Oncol. 2024;151:106717.
    >> Share

  46. CHEN QY, Guo SS, Luo Y, Qu S, et al
    Efficacy and safety of cadonilimab in previously treated recurrent or metastatic nasopharyngeal carcinoma(COMPASSION-06): A phase II multicenter study.
    Oral Oncol. 2024;151:106723.
    >> Share

  47. FANCELLO G, Jiang S, Licci G, Gallo O, et al
    Comments on the article titled "Factors associated with unknown primary status in head and neck squamous cell carcinoma": Is the N status the overlooked elephant in the room?
    Oral Oncol. 2024;151:106727.
    >> Share

  48. HU J, Huang Q, Hu W, Liang F, et al
    Tumor volume instead of recurrent T category predicts clinical outcome of patients with locally recurrent nasopharyngeal carcinoma salvaged by carbon ion radiation therapy.
    Oral Oncol. 2024;151:106683.
    >> Share

  49. CABEZAS-CAMARERO S, Vazquez Masedo G, Puebla-Diaz F, Corona JA, et al
    Major and durable responses to photon and electron-beam palliative radiotherapies after immune-checkpoint inhibitors in head and neck cancer.
    Oral Oncol. 2024;150:106719.
    >> Share

  50. SANTANA NCM, de Sena ACVP, Rocha PADS, de Arruda JAA, et al
    Oral cancer and oral potentially malignant disorders in patients with Fanconi anemia - A systematic review.
    Oral Oncol. 2024;150:106699.
    >> Share

  51. BATTISTI A, Della Monaca M, Di Giorgio D, Priore P, et al
    Extranodal follicular dendritic cell sarcoma of the tonsil: An extremely rare clinical entity.
    Oral Oncol. 2024;149:106690.
    >> Share

  52. ADEN AA, Olawuni FO, Abdel-Halim CN, Zhu AQ, et al
    Association Between Social Determinants of Health, Distance from Treatment Center, and Treatment Type with Outcomes in Human Papillomavirus Associated Oropharyngeal cancer.
    Oral Oncol. 2024;149:106675.
    >> Share

  53. HEIRMAN AN, Dirven R, van der Molen L, Schreuder WH, et al
    The development of a decision aid for patients with operable oropharyngeal carcinoma in the Netherlands - A mixed methods study.
    Oral Oncol. 2024;149:106677.
    >> Share

  54. MEIRELLES DP, Da Costa AAS, Sousa-Neto SS, Cardoso SV, et al
    Methodological challenges in identifying histological prognostic markers for squamous cell carcinoma of the lip, mouth, and oropharynx.
    Oral Oncol. 2024;149:106665.
    >> Share

  55. BALASAMY S, Sundramoorthy AK
    EGFR-targeted fluorescence imaging for precision margin assessment in oral cancer surgery.
    Oral Oncol. 2024;150:106712.
    >> Share

    January 2024
  56. OCHOA SCUSSIATTO H, Stenson KM, Al-Khudari S, Jelinek MJ, et al
    Air pollution is associated with increased incidence-rate of head and neck cancers: A nationally representative ecological study.
    Oral Oncol. 2024;150:106691.
    >> Share

  57. LI L, Chen L, Fan M, Tian Y, et al
    A prospective, single-arm trial of PD-1 inhibitors plus chemoradiotherapy for solitary metachronous metastasis nasopharyngeal carcinoma.
    Oral Oncol. 2024;150:106695.
    >> Share

  58. STOGBAUER F, Otto R, Johrens K, Tinhofer I, et al
    Molecular subtyping of head and neck cancer - Clinical applicability and correlations with morphological characteristics.
    Oral Oncol. 2024;149:106678.
    >> Share

  59. JAGADEESHAN S, Suryamohan K, Shin N, Mathukkada S, et al
    Evolutionary dynamics of tipifarnib in HRAS mutated head and neck squamous cell carcinoma.
    Oral Oncol. 2024;149:106688.
    >> Share

  60. PUJOL A, Leon X, Holgado A, Valero C, et al
    External validation of the GETTEC algorithm for elective neck dissection in patients candidates for salvage total laryngectomy.
    Oral Oncol. 2024;149:106686.
    >> Share

  61. SHENKER RF, Razavian NB, D'Agostino RB Jr, Mowery YM, et al
    Clinical outcomes of oropharyngeal squamous cell carcinoma stratified by human papillomavirus subtype: A systematic review and meta-analysis.
    Oral Oncol. 2024;148:106644.
    >> Share

  62. COSTANTINO A, Sampieri C, Pace GM, Festa BM, et al
    Development of machine learning models for the prediction of long-term feeding tube dependence after oral and oropharyngeal cancer surgery.
    Oral Oncol. 2024;148:106643.
    >> Share

    December 2023
  63. TOPKAN E, Somay E, Selek U
    Comment on "A systematic review and meta-analysis of osteoradionecrosis following proton therapy in patients with head and neck cancer".
    Oral Oncol. 2023;149:106679.
    >> Share

  64. AKHTAR A, Akhtar R, Nasir BM
    Response to "Integrating pretreatment MRI-detected nodal features and Epstein-Barr virus DNA to identify optimal candidates for intensity-modulated radiotherapy alone in patients with stage II nasopharyngeal carcinoma".
    Oral Oncol. 2023;149:106674.
    >> Share

  65. SICHERO L, Goncalves MG, Bettoni F, Coser EM, et al
    Detection of serum biomarkers of HPV-16 driven oropharynx and oral cavity cancer in Brazil.
    Oral Oncol. 2023;149:106676.
    >> Share

  66. BILA M, Franken A, Van Dessel J, Garip M, et al
    Exploring long-term responses to immune checkpoint inhibitors in recurrent and metastatic head and neck squamous cell carcinoma.
    Oral Oncol. 2023;149:106664.
    >> Share

  67. GUO Y, Nakashima T, Cho BC, Lim DW, et al
    Clinical decision pathway and management of locally advanced head and neck squamous cell carcinoma: A multidisciplinary consensus in Asia-Pacific.
    Oral Oncol. 2023;148:106657.
    >> Share

  68. HUANG H, Chen Z, Zhu M, Deng X, et al
    Discontinuation and nonpublication of nasopharyngeal carcinoma clinical trials.
    Oral Oncol. 2023;148:106656.
    >> Share

  69. CHEN W, Yu X, Li H, Yuan S, et al
    Single-cell RNA-seq reveals MIF-(CD74 + CXCR4) dependent inhibition of macrophages in metastatic papillary thyroid carcinoma.
    Oral Oncol. 2023;148:106654.
    >> Share

  70. NEO J, Yip PL, Ong EHW, Miao J, et al
    Longitudinal post-radiotherapy plasma Epstein-Barr virus DNA trends inform on optimal risk stratification in endemic nasopharyngeal carcinoma.
    Oral Oncol. 2023;148:106655.
    >> Share

  71. WILLIAMSON A, Moen CM, Slim MAM, Warner L, et al
    Transoral robotic surgery without adjuvant therapy: A systematic review and meta-analysis of the association between surgical margins and local recurrence.
    Oral Oncol. 2023;147:106610.
    >> Share

  72. SILVA CUNHA JL
    Comment on "Decisional regret, symptom burden, and quality of life following transoral robotic surgery for oropharyngeal cancer".
    Oral Oncol. 2023;147:106626.
    >> Share

  73. TIRELLI G, Boscolo-Rizzo P
    Palatoglossus muscle involvement in oropharynx Carcinoma: A pitfall in the T4 category definition of the 8th edition of the TNM staging system?
    Oral Oncol. 2023;147:106627.
    >> Share

  74. BARROS EF, Cunha JLS, de Sousa DP, Pereira RVS, et al
    A destructive sinonasal organizing hematoma mimicking malignancy.
    Oral Oncol. 2023;147:106619.
    >> Share

    November 2023
  75. KALAVACHERLA S, Li V, Voora R, Victor M, et al
    Factors associated with unknown primary status in head and neck squamous cell carcinoma.
    Oral Oncol. 2023;148:106650.
    >> Share

  76. ZHANG S, Zheng M, Tian H, Liu W, et al
    Are immune checkpoint inhibitors ineffective in treating patients with head and neck squamous cell carcinoma aged 75 years or Older? A Meta-Analysis.
    Oral Oncol. 2023;148:106632.
    >> Share

  77. CHIU KW, Yu TP, Kao YS
    A systematic review and meta-analysis of osteoradionecrosis following proton therapy in patients with head and neck cancer.
    Oral Oncol. 2023;148:106649.
    >> Share

  78. DE SENA ACVP, de Arruda JAA, Felix FA, Tavares TS, et al
    Oral carcinoma in situ in a middle-aged woman with systemic sclerosis: Report of a rare case and literature review.
    Oral Oncol. 2023;148:106646.
    >> Share

  79. HES C, Desilets A, Tonneau M, El Ouarzadi O, et al
    Gut microbiome predicts gastrointestinal toxicity outcomes from chemoradiation therapy in patients with head and neck squamous cell carcinoma.
    Oral Oncol. 2023;148:106623.
    >> Share

  80. GAFFNEY J, Ramzan A, Dinizulu T, Maley C, et al
    Association of follow-up imaging frequency with temporal incidence and patterns of distant failure following (chemo) radiotherapy for HPV related oropharyngeal cancer.
    Oral Oncol. 2023;148:106645.
    >> Share

  81. CHEN AM, Harris JP, Tjoa T, Haidar Y, et al
    Racial disparities in the timely receipt of adjuvant radiotherapy for head and neck cancer.
    Oral Oncol. 2023;147:106611.
    >> Share

  82. TAKESHITA N, Enokida T, Okano S, Fujisawa T, et al
    Weekly paclitaxel, carboplatin and cetuximab (PCE) combination followed by nivolumab for recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN).
    Oral Oncol. 2023;147:106615.
    >> Share

  83. YU SM, Hsu CC, Hsueh SW, Hung CY, et al
    Frailty assessment by two screening instruments in non-elderly patients with head and neck cancer.
    Oral Oncol. 2023;147:106621.
    >> Share

  84. HARRINGTON KJ, Cohen EEW, Soulieres D, Dinis J, et al
    Pembrolizumab versus methotrexate, docetaxel, or cetuximab in recurrent or metastatic head and neck squamous cell carcinoma (KEYNOTE-040): Subgroup analysis by pattern of disease recurrence.
    Oral Oncol. 2023;147:106587.
    >> Share

  85. ABDEL-HALIM CN, O'Byrne TJ, Graves JP, Akpala CO, et al
    Patterns and distribution of regional nodal involvement and recurrence in a surgically treated oropharyngeal squamous cell carcinoma cohort at a tertiary center.
    Oral Oncol. 2023;146:106569.
    >> Share

  86. BARTEMES KR, Gochanour BR, Routman DM, Ma DJ, et al
    Assessing the capacity of methylated DNA markers of cervical squamous cell carcinoma to discriminate oropharyngeal squamous cell carcinoma in human papillomavirus mediated disease.
    Oral Oncol. 2023;146:106568.
    >> Share

  87. WARD MC, Wallander ML, Kuremsky JG, Dhakal R, et al
    Radiation therapy for cT1-2 carcinoma of the palatine tonsil diagnosed via a simple tonsillectomy: Dosimetry and patterns of care in the IMRT era.
    Oral Oncol. 2023;146:106557.
    >> Share

  88. KWON JJY, Liu AQ, Milner TD, Prisman E, et al
    Decisional regret, symptom burden, and quality of life following transoral robotic surgery for oropharyngeal cancer.
    Oral Oncol. 2023;146:106537.
    >> Share

  89. HERMSEN MA, Lechner M, Oliveira Ferrer L, Trama A, et al
    EUSICA/COST IMMUNO-model workshop fostering collaboration to advance sinonasal cancer research: A meeting report.
    Oral Oncol. 2023;146:106543.
    >> Share

  90. SARODE GS, Sarode SC, Sharma N
    Comment on "Clonal evolution of long-term expanding head and neck cancer organoid: Impact on treatment response for personalized therapeutic screening".
    Oral Oncol. 2023;147:106614.
    >> Share

    October 2023
  91. ANSARI E, Ganry L, Van Cann EM, de Bree R, et al
    Impact of low skeletal muscle mass on postoperative complications in head and neck cancer patients undergoing free flap reconstructive surgery - A systematic review and meta-analysis.
    Oral Oncol. 2023;147:106598.
    >> Share

  92. LIU ZQ, Zhao YN, Wu YS, Zhang BY, et al
    Immunochemotherapy alone or immunochemotherapy plus subsequent locoregional radiotherapy in de novo metastatic nasopharyngeal carcinoma.
    Oral Oncol. 2023;147:106583.
    >> Share

  93. BATOOL S, Sethi RKV, Wang A, Dabekaussen K, et al
    Circulating tumor-tissue modified HPV DNA testing in the clinical evaluation of patients at risk for HPV-positive oropharynx cancer: The IDEA-HPV study.
    Oral Oncol. 2023;147:106584.
    >> Share

  94. SARAVANAN M, Sampath S, Arockiaraj J
    The use of advanced transoral robotic surgery in the treatment of oropharynx squamous cell carcinoma: A modern alternative for open surgery.
    Oral Oncol. 2023;145:106522.
    >> Share

  95. TURNER MT, Chung J, Noorkbash S, Topf MC, et al
    Complications following salvage transoral robotic surgery with and without reconstruction: A systematic review of the literature.
    Oral Oncol. 2023;145:106467.
    >> Share

  96. ROBERTI E, Merlano M, Ravanelli M, Alberti A, et al
    Muscle quality and not quantity as a predictor of survival in head and neck squamous cell carcinoma.
    Oral Oncol. 2023;145:106540.
    >> Share

  97. REVERDY T, Varnier R, de Talhouet S, Duplomb S, et al
    Analysis of the benefit of salvage chemotherapy after progression on nivolumab in patients with squamous cell carcinoma of the head and neck.
    Oral Oncol. 2023;145:106533.
    >> Share

  98. KEMNADE JO, Florez M, Sabichi A, Zhang J, et al
    Phase I / II trial of metformin as a chemo-radiosensitizer in a head and neck cancer patient population.
    Oral Oncol. 2023;145:106536.
    >> Share

    September 2023
  99. SHAIKH MH, Dawson A, Prokopec SD, Barrett JW, et al
    Loss of LRP1B expression drives acquired chemo and radio-resistance in HPV-positive head and neck cancer.
    Oral Oncol. 2023;146:106580.
    >> Share

  100. CAVALIERI S, Platini F, Barretta F, Nuzzolese I, et al
    Pre-treatment risk factors to predict early cisplatin-related nephrotoxicity in locally advanced head and neck cancer patients treated with chemoradiation: A single Institution experience.
    Oral Oncol. 2023;146:106579.
    >> Share

  101. MALI SB
    Role of in vivo imaging in Head and Neck cancer management.
    Oral Oncol. 2023;146:106575.
    >> Share

  102. CHOI SY, Shim J, Gu DE, Kim SY, et al
    Clonal evolution of long-term expanding head and neck cancer organoid: Impact on treatment response for personalized therapeutic screening.
    Oral Oncol. 2023;146:106571.
    >> Share

  103. GUO J, He Y, Lin C, Jiang Q, et al
    Integrating pretreatment MRI-detected nodal features and Epstein-Barr virus DNA to identify optimal candidates for intensity-modulated radiotherapy alone in patients with stage II nasopharyngeal carcinoma.
    Oral Oncol. 2023;146:106574.
    >> Share

  104. SINGH R, Song S
    Clinical outcomes following observation, post-operative radiation therapy, or post-operative chemoradiation for HPV-associated oropharyngeal squamous cell carcinomas.
    Oral Oncol. 2023;146:106493.
    >> Share

  105. SHAH R, Tyagi S, Liu C, Judson B, et al
    Extra imaging beyond NCCN surveillance guidelines is cost effective for HPV- but not HPV+ oropharyngeal cancer.
    Oral Oncol. 2023;146:106564.
    >> Share

  106. MANN JE, Smith JD, Kulkarni A, Foltin SK, et al
    Genome-wide open reading frame profiling identifies fibroblast growth factor signaling as a driver of PD-L1 expression in head and neck squamous cell carcinoma.
    Oral Oncol. 2023;146:106562.
    >> Share

  107. SAHA S, Patil VM, Noronha V, Menon N, et al
    Real world data on long term outcome of neoadjuvant chemotherapy in locally advanced esthesioneuroblastoma and sinonasal tumor with neuroendocrine differentiation - Results from a single centre study.
    Oral Oncol. 2023;144:106486.
    >> Share

  108. CANAHUATE G, Wentzel A, Mohamed ASR, van Dijk LV, et al
    Spatially-aware clustering improves AJCC-8 risk stratification performance in oropharyngeal carcinomas.
    Oral Oncol. 2023;144:106460.
    >> Share

    August 2023
  109. VIEIRA GS, Perin MY, Figueiredo-Maciel T, Risuenho AJG, et al
    Induction chemotherapy response of HPV-related multiphenotypic sinonasal carcinoma: First-ever reported therapeutic outcome and a brief literature review.
    Oral Oncol. 2023;146:106555.
    >> Share

  110. XU YC, Chen KH, Liang Y, Chen KQ, et al
    Efficacy of induction chemotherapy in lymph node-positive stage III nasopharyngeal carcinoma and identification of beneficiaries based on clinical features: A propensity score matching analysis.
    Oral Oncol. 2023;146:106554.
    >> Share

  111. TASOULAS J, Schrank TP, Smith BD, Agala CB, et al
    Time to treatment patterns of head and neck cancer patients before and during the Covid-19 pandemic.
    Oral Oncol. 2023;146:106535.
    >> Share

  112. CHARTERS E, Loy J, Wu R, Cheng K, et al
    Feasibility study of intensive intervention using novel trismus device during adjuvant radiation for head and neck cancer: Restorabite(TM).
    Oral Oncol. 2023;146:106558.
    >> Share

  113. AL-MANEI K, Sobkowiak MJ, Nagadia RH, Heymann R, et al
    Mycobiota profile of oral fungal infections in head and neck cancer patients receiving radiotherapy: A 6-year retrospective MALDI-TOF mass spectrometry study.
    Oral Oncol. 2023;146:106556.
    >> Share

  114. ZHANG L, Liao Y
    Comment on: Efficacy of Anti-PD1 blockade in treating recurrent or metastatic nasopharyngeal cancer: A systematic review and meta-analysis.
    Oral Oncol. 2023;143:106435.
    >> Share

  115. BHAMBHANI C, Sandford E, Haring CT, Brummel C, et al
    Development of a high-performance multi-probe droplet digital PCR assay for high-sensitivity detection of human papillomavirus circulating tumor DNA from plasma.
    Oral Oncol. 2023;143:106436.
    >> Share

    July 2023
  116. DOLL C, Bigus S, Hofmann E, Mrosk F, et al
    Sentinel lymph node biopsy in recurrent or secondary oral squamous cell carcinoma after previous neck dissection.
    Oral Oncol. 2023;145:106494.
    >> Share

  117. GAN M, Harris JP, Truong A, Nabar R, et al
    Timing of chemotherapy and radiation delivery for patients receiving chemoradiation for head and neck cancer: When does "concurrent" mean concurrent?
    Oral Oncol. 2023;145:106492.
    >> Share

  118. MULLER M, Li J, Giger R, Elicin O, et al
    Head and neck cancer with synchronous nodules of the lung as a diagnostic and therapeutic challenge - A systematic review.
    Oral Oncol. 2023;145:106529.
    >> Share

  119. WEI F, Fang R, Lyu K, Liao J, et al
    Exosomal PD-L1 derived from head and neck squamous cell carcinoma promotes immune evasion by activating the positive feedback loop of activated regulatory T cell-M2 macrophage.
    Oral Oncol. 2023;145:106532.
    >> Share

  120. WATSON E, El Maghrabi A, Lee JH, Pu J, et al
    Implication of dental insurance status on patterns of pre-radiation dental extraction and risk of osteoradionecrosis of the jaw in head-and-neck cancer patients.
    Oral Oncol. 2023;145:106527.
    >> Share

  121. NEWMAN S, Cowart JH, Omar N, Martin E, et al
    HPV-associated oropharyngeal Adenosquamous carcinoma with early metastatic disease detected by ctDNA.
    Oral Oncol. 2023;145:106526.
    >> Share

  122. HAN N, Zhou D, Ruan M, Yan M, et al
    Cancer cell-derived extracellular vesicles drive pre-metastatic niche formation of lymph node via IFNGR1/JAK1/STAT1-activated-PD-L1 expression on FRCs in head and neck cancer.
    Oral Oncol. 2023;145:106524.
    >> Share

  123. NGAMPHAIBOON N, Chairoungdua A, Dajsakdipon T, Jiarpinitnun C, et al
    Evolving role of novel radiosensitizers and immune checkpoint inhibitors in (chemo)radiotherapy of locally advanced head and neck squamous cell carcinoma.
    Oral Oncol. 2023;145:106520.
    >> Share

  124. WANG G, Dong Z, Huang C, Du X, et al
    The value of integrating tumor volume and plasma Epstein-Barr virus DNA load during sequential chemoradiotherapy for prognostic prediction and therapeutic guidance in high-risk locoregionally advanced nasopharyngeal carcinoma.
    Oral Oncol. 2023;145:106500.
    >> Share

  125. VIMALRAJ S, Sekaran S
    Exploring the potential of MiRNAs as predictive biomarkers for radioresistance in nasopharyngeal carcinoma.
    Oral Oncol. 2023;145:106521.
    >> Share

  126. YOKOTA Y, Hasegawa T, Yamakawa N, Rin S, et al
    Comparison of the 8th edition of TNM staging of oral cancer with the 7th edition and its prognostic significance using clinical depth of invasion and extranodal extension.
    Oral Oncol. 2023;145:106519.
    >> Share

  127. KO K, Takahashi T, Honda K, Horii A, et al
    Avoiding total thyroidectomy for ectopic papillary thyroid carcinoma arising from the lateral neck.
    Oral Oncol. 2023;145:106501.
    >> Share

  128. LI D, Li C, Shi S
    Letter to the editor: The efficacy and safety of VEGF/VEGFR inhibitors in patients with recurrent or metastatic nasopharyngeal carcinoma.
    Oral Oncol. 2023;145:106497.
    >> Share

  129. PENG WS, Xing X, Li YJ, Ding JH, et al
    Prognostic nomograms for nasopharyngeal carcinoma with nodal features and potential indication for N staging system: Validation and comparison of seven N stage schemes.
    Oral Oncol. 2023;144:106438.
    >> Share

  130. ZENGA J, Awan M, Hadi Razeghi Kondelaji M, Hansen C, et al
    Photoactivated HPPH-Liposomal therapy for the treatment of HPV-Negative head and neck cancer.
    Oral Oncol. 2023;144:106487.
    >> Share

  131. CHEPEHA DB, Esemezie AO, Philteos J, Brown DH, et al
    Glossectomy for the treatment of oral cavity carcinoma: Quantitative, functional and patient-reported quality of life outcomes differ by four glossectomy defects.
    Oral Oncol. 2023;142:106431.
    >> Share

  132. EVERTON ASSUNCAO RIBEIRO DA CO, Luz Santos I, Julia Andrade Pereira Soares M, Dos Reis de Paula I, et al
    A case of metastatic NUT carcinoma of the nasal cavity.
    Oral Oncol. 2023;142:106432.
    >> Share

    June 2023
  133. HE M, Gouda M, Gires O
    EpCAM and EGFR crosstalk in the development of resistance towards Cetuximab treatment in head and neck cancer.
    Oral Oncol. 2023;143:106465.
    >> Share

  134. YEUNG C, Meyers BM, Kartolo A
    Management of metastatic head and neck Cancer: An all-in, kitchen-sink Approach?
    Oral Oncol. 2023;143:106444.
    >> Share

  135. KOYUNCU CF, Frederick MJ, Thompson LDR, Corredor G, et al
    Machine learning driven index of tumor multinucleation correlates with survival and suppressed anti-tumor immunity in head and neck squamous cell carcinoma patients.
    Oral Oncol. 2023;143:106459.
    >> Share

  136. PANDIAR D, Nayanar SK, Nair V
    Papillary thyroid carcinoma arising in thyroglossal duct cyst: A case report with long term follow-up.
    Oral Oncol. 2023;143:106439.
    >> Share

    May 2023
  137. UMEMORI K, Ono K, Eguchi T, Kawai H, et al
    EpEX, the soluble extracellular domain of EpCAM, resists cetuximab treatment of EGFR-high head and neck squamous cell carcinoma.
    Oral Oncol. 2023;142:106433.
    >> Share

  138. HIGGINSON JA, Breik O, Thompson AH, Ashrafian H, et al
    Diagnostic accuracy of intraoperative margin assessment techniques in surgery for head and neck squamous cell carcinoma: A meta-analysis.
    Oral Oncol. 2023;142:106419.
    >> Share

  139. WARNAKULASURIYA S
    "Textbook outcome" as a quality metric of care in predicting survival from oral cancer.
    Oral Oncol. 2023;141:106416.
    >> Share

  140. DING H, Wu C, Sun W, Zhan Q, et al
    NUDT5-Determines the fate of head and neck squamous cell carcinoma cells under endoplasmic reticulum stress by catalyzing nuclear ATP production to promote DNA repair.
    Oral Oncol. 2023;141:106397.
    >> Share

  141. WANG Y, Gao Y, Yuan L, Zhang J, et al
    Retraction notice to "Psychological needs and associated factors among perioperative patients with oral cancer" [Oral Oncol. 123 (2021) 105615].
    Oral Oncol. 2023 May 5:106394. doi: 10.1016/j.oraloncology.2023.106394.
    >> Share

  142. RETTIG EM, Waterboer T, Sim E, Faden DL, et al
    Relationship of HPV16 E6 seropositivity with circulating tumor tissue modified HPV16 DNA before head and neck cancer diagnosis.
    Oral Oncol. 2023;141:106417.
    >> Share

    April 2023
  143. MISRA SR, Mohapatra SSG, Das R
    Comment on "Elective neck dissection: Desideratum or overkill?".
    Oral Oncol. 2023;141:106403.
    >> Share

  144. HUE J, Valinciute Z, Thavaraj S, Veschini L, et al
    Multifactorial estimation of clinical outcome in HPV-associated oropharyngeal squamous cell carcinoma via automated image analysis of routine diagnostic H&E slides and neural network modelling.
    Oral Oncol. 2023;141:106399.
    >> Share

  145. BOSCOLO-RIZZO P, Tirelli G, Polesel J, Sia E, et al
    TERT promoter mutations in head and neck squamous cell carcinoma: A systematic review and meta-analysis on prevalence and prognostic significance.
    Oral Oncol. 2023;140:106398.
    >> Share

  146. YANG TH, Xirasagar S, Cheng YF, Chen CS, et al
    Trends in the incidence of head and neck cancer: A nationwide population-based study.
    Oral Oncol. 2023;140:106391.
    >> Share

  147. MERCHANT YP, Shah A
    Elective neck dissection: Desideratum or overkill?
    Oral Oncol. 2023;140:106389.
    >> Share

  148. ARAUJO ALD, Moraes MC, Perez-de-Oliveira ME, Silva VMD, et al
    Machine learning for the prediction of toxicities from head and neck cancer treatment: A systematic review with meta-analysis.
    Oral Oncol. 2023;140:106386.
    >> Share

  149. PATEL ND, Cabrera CI, Fowler NM, Li S, et al
    Incidence and medical complications of COVID-19 in the total laryngectomy population: A population-based study.
    Oral Oncol. 2023;139:106353.
    >> Share

  150. COMER JC, Harris AB, Hess AO, Hitchcock KE, et al
    Does lymphovascular invasion predict survival in oral cancer? A population-based analysis.
    Oral Oncol. 2023;140:106387.
    >> Share

    March 2023
  151. ZUO N, Ma L, Liu T, Hu W, et al
    Human papillomavirus associated XPF deficiency increases alternative end joining and cisplatin sensitivity in head and neck squamous cell carcinoma.
    Oral Oncol. 2023;140:106367.
    >> Share

  152. SAMPIERI C, Costantino A, Pirola F, Kim D, et al
    Neoadjuvant chemotherapy combined with transoral robotic surgery for stage III and IV laryngeal and hypopharyngeal carcinomas.
    Oral Oncol. 2023;140:106371.
    >> Share

  153. HERNANDO-CALVO A, Mirallas O, Marmolejo D, Saavedra O, et al
    Nutritional status associates with immunotherapy clinical outcomes in recurrent or metastatic head and neck squamous cell carcinoma patients.
    Oral Oncol. 2023;140:106364.
    >> Share

  154. CHIEN CY, Wang CP, Lee LY, Lee SR, et al
    Indications for elective neck dissection in cT1N0M0 oral cavity cancer according to the AJCC eight edition: A nationwide study.
    Oral Oncol. 2023;140:106366.
    >> Share

  155. LAMBERT T, Tasoulas J, Flores M, Sheth S, et al
    Circulating tumor HPV DNA as an alternative method to determine HPV status in oropharyngeal squamous cell carcinoma.
    Oral Oncol. 2023;140:106361.
    >> Share

  156. SCHEFF NN, Nilsen ML, Li J, Harris AL, et al
    The effect of opioids on the efficacy of immunotherapy in recurrent/metastatic squamous cell carcinoma of the head and neck.
    Oral Oncol. 2023;140:106363.
    >> Share

  157. BANOUB RG, Crippen MM, Fiorella MA, Ross HM, et al
    Variance in 3D anatomic localization of surgical margins based on conventional margin labeling in head and neck squamous cell carcinoma.
    Oral Oncol. 2023;139:106360.
    >> Share

  158. ZHANG L, Freeman T, Sun S, Bhateja P, et al
    The use of plasma circulating tumor DNA for early detection of oligometastatic disease in HPV positive oropharyngeal squamous cell carcinoma.
    Oral Oncol. 2023;139:106357.
    >> Share

  159. DE FELICE F
    Docetaxel plus radiotherapy for head and neck cancer.
    Oral Oncol. 2023;139:106359.
    >> Share

  160. ECONOMOPOULOU P, Spathis A, Kotsantis I, Maratou E, et al
    Next-generation sequencing (NGS) profiling of matched tumor and circulating tumor DNA (ctDNA) in head and neck squamous cell carcinoma (HNSCC).
    Oral Oncol. 2023;139:106358.
    >> Share

  161. DE SOUSA LG, Lazar Neto F, Dal Lago EA, Sikora A, et al
    Human papillomavirus status and prognosis of oropharyngeal high-grade neuroendocrine carcinoma.
    Oral Oncol. 2023;138:106311.
    >> Share

    February 2023
  162. LI SC, Deng SW, Sun XS, Lan KQ, et al
    A new prognostic model for predicting outcomes of patients with recurrent or metastatic nasopharyngeal carcinoma receiving subsequent line (>/=2 lines) anti-programmed death-1 monotherapy.
    Oral Oncol. 2023;139:106336.
    >> Share

  163. GUERLAIN J, Marhic A, Casiraghi O, Lumbroso J, et al
    Occult nodal metastases in T1-T2cN0 oral squamous cell carcinoma: Correlation between sentinel node positivity and completion neck dissection analysis.
    Oral Oncol. 2023;139:106338.
    >> Share

  164. PARIKH AS, Yu VX, Flashner S, Okolo OB, et al
    Patient-derived three-dimensional culture techniques model tumor heterogeneity in head and neck cancer.
    Oral Oncol. 2023;138:106330.
    >> Share

  165. XIAO Y, Mao L, Yang QC, Wang S, et al
    CD103 blockade impair anti-CTLA-4 immunotherapy in oral cancer.
    Oral Oncol. 2023;138:106331.
    >> Share

  166. RYGALSKI CJ, Huttinger ZM, Zhao S, Brock G, et al
    High surgical volume is associated with improved survival in head and neck cancer.
    Oral Oncol. 2023;138:106333.
    >> Share

  167. BALLAL Y, Gete M, Su J, O'Sullivan B, et al
    The collateral impact of the COVID-19 pandemic on HPV-positive oropharyngeal cancer diagnosis.
    Oral Oncol. 2023;138:106332.
    >> Share

  168. BOOT PA, Mes SW, de Bloeme CM, Martens RM, et al
    Magnetic resonance imaging based radiomics prediction of Human Papillomavirus infection status and overall survival in oropharyngeal squamous cell carcinoma.
    Oral Oncol. 2023;137:106307.
    >> Share

    January 2023
  169. VAN BEERS MA, Schreuder WH, Balm AJM, van Dijk BAC, et al
    Is locally advanced head and neck cancer 'increasing' in the Netherlands? The paradox of absolute numbers, standardized incidence rates and proportional share.
    Oral Oncol. 2023;138:106316.
    >> Share

  170. PELLET A, Bertolus C, Saintigny P, Foy JP, et al
    Reliability of gene-expression profiling from tumor biopsy for refining neoadjuvant strategies in patients with head and neck squamous cell carcinoma.
    Oral Oncol. 2023;138:106310.
    >> Share

  171. ROBBINS Y, Friedman J, Redman J, Sievers C, et al
    Tumor cell HLA class I expression and pathologic response following neoadjuvant immunotherapy for newly diagnosed head and neck cancer.
    Oral Oncol. 2023;138:106309.
    >> Share

  172. WINNAND P, Ooms M, Heitzer M, Lammert M, et al
    Real-time detection of bone-invasive oral cancer with laser-induced breakdown spectroscopy: A proof-of-principle study.
    Oral Oncol. 2023;138:106308.
    >> Share

  173. WU Z, Han Y, Wan Y, Hua X, et al
    Oral microbiome and risk of incident head and neck cancer: A nested case-control study.
    Oral Oncol. 2023;137:106305.
    >> Share

  174. ARGYRIS PP, Saavedra F, Malz C, Stone IA, et al
    Intracellular calprotectin (S100A8/A9) facilitates DNA damage responses and promotes apoptosis in head and neck squamous cell carcinoma.
    Oral Oncol. 2023;137:106304.
    >> Share

  175. YEO BSY, Song HJJMD, Soong YL, Chua MLK, et al
    Efficacy of Anti-PD1 Blockade in Treating Recurrent or Metastatic Nasopharyngeal Cancer: A Systematic Review and Meta-analysis.
    Oral Oncol. 2023;136:106242.
    >> Share

  176. ADEOYE J, Zheng LW, Thomson P, Choi SW, et al
    Explainable ensemble learning model improves identification of candidates for oral cancer screening.
    Oral Oncol. 2023;136:106278.
    >> Share

    December 2022
  177. IDA S, Takahashi H, Tada H, Mito I, et al
    Dynamic changes of the EMT spectrum between circulating tumor cells and the tumor microenvironment in human papillomavirus-positive head and neck squamous cell carcinoma.
    Oral Oncol. 2022;137:106296.
    >> Share

  178. GHEENA S, Ezhilarasan D
    Personalized mRNA cancer vaccines with immune checkpoint inhibitors: A promising therapeutic approach in oral cancer patients.
    Oral Oncol. 2022;137:106282.
    >> Share

  179. DE FELICE F, Bossi P
    Pembrolizumab with or without chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma: Hypothesis coming from the subgroup analysis.
    Oral Oncol. 2022;137:106275.
    >> Share

  180. PERES MA, Huihua L, Antunes JLF, Perea LME, et al
    Time trend and Age-Period-Cohort analysis of potentially HPV-related oral and pharyngeal cancer incidence in Singapore between 1968 and 2017.
    Oral Oncol. 2022;136:106272.
    >> Share

  181. TAZEEN S, Suri H, Lakshmi R, Subash A, et al
    Swallowing: A delayed milestone post-surgery in tongue cancers.
    Oral Oncol. 2022;135:106238.
    >> Share

  182. TAVERNA F, Alfieri S, Rebecca R, Giulia C, et al
    Comparing BamHI-W and CE-marked assays to detect circulating Epstein-Barr Virus (EBV) DNA of nasopharyngeal cancer patients in a non-endemic area.
    Oral Oncol. 2022;135:106229.
    >> Share

  183. GUNAWARDENA DA, Howes D, Fleming S, Clark J, et al
    Reconstruction of a maxillectomy and rhinectomy defect utilising a novel subperiosteal prosthesis and magnet-retained nasal prosthesis: A case report.
    Oral Oncol. 2022;135:106222.
    >> Share

  184. TAPIA M, Manji J, Dhillon K, Kleid S, et al
    The negative predictive value of FDG PET/CT staging in early oropharyngeal squamous cell carcinoma and implications to transoral robotic surgery patient selection.
    Oral Oncol. 2022;135:106213.
    >> Share

    November 2022
  185. MITO I, Takahashi H, Kawabata-Iwakawa R, Horikawa M, et al
    Tumor-derived exosomes elicit cancer-associated fibroblasts shaping inflammatory tumor microenvironment in head and neck squamous cell carcinoma.
    Oral Oncol. 2022;136:106270.
    >> Share

  186. KIRAN NAZEER P, Shaheen S, Shafique K, Sarfraz A, et al
    The role of precision medicine in head and neck cancer: A systematic study of ongoing clinical trials.
    Oral Oncol. 2022;136:106271.
    >> Share

  187. PENG Y, Liu Y, Shen G, Chen Z, et al
    Improved accuracy of auto-segmentation of organs at risk in radiotherapy planning for nasopharyngeal carcinoma based on fully convolutional neural network deep learning.
    Oral Oncol. 2022;136:106261.
    >> Share

  188. MANZOOR H, Rasheed A, Zeen F, Sarfraz A, et al
    Anti-PD-1 immunotherapy - Pembrolizumab current clinical trials for advanced head and neck cancer: A mapping systematic study.
    Oral Oncol. 2022;136:106266.
    >> Share

  189. LIU HC, Williamson CW, Zou J, Todd JR, et al
    Quantitative prediction of aspiration risk in head and neck cancer patients treated with radiation therapy.
    Oral Oncol. 2022;136:106247.
    >> Share

  190. CHAN JYK, Cheung MK, Lan L, Ng C, et al
    Characterization of oral microbiota in HPV and non-HPV head and neck squamous cell carcinoma and its association with patient outcomes.
    Oral Oncol. 2022;135:106245.
    >> Share

  191. KMIECIK M, Nogal P, Banaszewski J, Wierzbicka M, et al
    Corrigendum to "Anterolateral thigh free flap reconstruction of pharyngoesophageal defect caused by radiotherapy for laryngeal cancer: A case report" [Oral Oncol. 134 (2022) 106135].
    Oral Oncol. 2022 Nov 4:106233. doi: 10.1016/j.oraloncology.2022.106233.
    >> Share

  192. QUAN T, Guan W, Huang W, Cui C, et al
    Carotid space involvement is a prognostic factor and marker for induction chemotherapy in patients with nasopharyngeal carcinoma.
    Oral Oncol. 2022;135:106230.
    >> Share

  193. BISHESHAR SK, van der Kamp MF, de Ruiter EJ, Ruiter LN, et al
    The prognostic role of tumor associated macrophages in squamous cell carcinoma of the head and neck: A systematic review and meta-analysis.
    Oral Oncol. 2022;135:106227.
    >> Share

  194. CHIDAMBARAM S, Hong SA, Simpson MC, Osazuwa-Peters N, et al
    Temporal trends in oropharyngeal cancer incidence, survival, and cancer-directed surgery among elderly Americans.
    Oral Oncol. 2022;134:106132.
    >> Share

  195. AROSIO AD, Bernasconi DP, Valsecchi MG, Pacifico C, et al
    Patterns of recurrences in sinonasal cancers undergoing an endoscopic surgery-based treatment: Results of the MUSES* on 940 patients: *MUlti-institutional collaborative Study on Endoscopically treated Sinonasal cancers.
    Oral Oncol. 2022;134:106123.
    >> Share

  196. MANJUSHA M, Saravanan M
    Oropharyngeal cancer associated with sarcopenic obesity and sarcopenic weight loss.
    Oral Oncol. 2022;134:106101.
    >> Share

  197. FITZGERALD CWR, Davies JC, de Almeida JR, Rich JT, et al
    Factors predicting pharyngocutaneous fistula in patients after salvage laryngectomy for laryngeal malignancy - A multicenter collaborative cohort study.
    Oral Oncol. 2022;134:106089.
    >> Share

  198. DE LUCA P, Scarpa A, Viola P, Motta G, et al
    Collision tumors of the larynx: A retrospective single-center case series of an extremely rare phenomenon.
    Oral Oncol. 2022;134:106096.
    >> Share

  199. WEINBERGER JM, Abd El Qadir N, Hirshoren N
    Double trouble: A cohort study of re-irradiation and laryngectomy - Severity of and risk for pharyngocutaneous fistula.
    Oral Oncol. 2022;134:106069.
    >> Share

  200. DE BREE R, Leemans CR
    When to perform a paratracheal lymph node dissection during total laryngectomy?
    Oral Oncol. 2022;134:106048.
    >> Share

  201. WU B, Shen L, Peng G, Li Y, et al
    Molecular characteristics of pediatric nasopharyngeal carcinoma using whole-exome sequencing.
    Oral Oncol. 2022;135:106218.
    >> Share

  202. HUANG J, Harris E, Lorch J
    Vaccination as a therapeutic strategy for Nasopharyngeal carcinoma.
    Oral Oncol. 2022;135:106083.
    >> Share

    October 2022
  203. XUE S, Song G, Zhu Y, Zhang N, et al
    The efficacy and safety of VEGF/VEGFR inhibitors in patients with recurrent or metastatic nasopharyngeal carcinoma: A meta-analysis.
    Oral Oncol. 2022;135:106231.
    >> Share

  204. KAO DD, Ferrandino RM, Bauml JM, Marshall DC, et al
    Prophylactic feeding tube placement for squamous cell carcinoma of the head and neck.
    Oral Oncol. 2022;135:106216.
    >> Share

  205. ZHU L, Li M, Tang G, Shi L, et al
    Role of salivary miRNAs as noninvasive biomarkers in head and neck squamous cell carcinomas and oral potentially malignant disorders - Reply.
    Oral Oncol. 2022;135:106224.
    >> Share

  206. DENNIS MJ, Sacco AG, Qi Y, Bykowski J, et al
    A phase I study of avelumab, palbociclib, and cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma.
    Oral Oncol. 2022;135:106219.
    >> Share

  207. GOVINDARASU M, Prathap L, Govindasamy R
    Histone deacetylase inhibitors regulate the oral cancer via PI3K/AKT signaling pathway.
    Oral Oncol. 2022;135:106221.
    >> Share

  208. CHABRILLAC E, Lebars S, Breuskin I, Thariat J, et al
    Pregnancy-associated head and neck cancer:a partnership between theCORASSO patient association and theREFCOR physician networkto study a pathology of extremely rare occurrence.
    Oral Oncol. 2022;135:106223.
    >> Share

  209. OLAWUNI FO, Sauer AB, Daher GS, Douse DM, et al
    The reporting and representation of sex and gender in head and neck cancer clinical trials.
    Oral Oncol. 2022;135:106217.
    >> Share

  210. SUNDRAMOORTHY AK, Atchudan R, Arya S
    Utilization of Raman spectroscopy in biochemical fingerprint analysis for oral cancer screening and diagnosis.
    Oral Oncol. 2022;135:106192.
    >> Share

  211. ZHU L, Deng Y, Ji T, Zhou H, et al
    Metformin and oral cancer: In reply with emphasis on an emerging role of an old drug in oral cancer chemoprevention.
    Oral Oncol. 2022;135:106196.
    >> Share

  212. MANJUSHA M, Saravanan M
    Development of novel electrochemical based nano-biosensors for the diagnosis of oral potentially malignant disorders and oral carcinoma.
    Oral Oncol. 2022;135:106197.
    >> Share

  213. SEKAR AA, Veeraraghavan VP, Raj AT, Patil S, et al
    Unravelling the long non-coding RNA, CYTOR can serve as a potential therapeutic target in oral cancer.
    Oral Oncol. 2022;135:106195.
    >> Share

  214. GURMEET SINGH A, Sathe P, Roy S, Thiagrajan S, et al
    Incidence and impact of skip metastasis in the neck in early oral cancer: Reality or a myth?
    Oral Oncol. 2022;135:106201.
    >> Share

  215. KRISHNAMOORTHY K, Priya Veeraraghavan V, Jayaraman S
    E3 ubiquitin ligases: A therapeutic drug target in head and neck squamous cell carcinoma.
    Oral Oncol. 2022;135:106193.
    >> Share

  216. ZHU S, Zhang F, Zhao G, Zhang X, et al
    Trends in the global burden of oral cancer joint with attributable risk factors: Results from the global burden of disease study 2019.
    Oral Oncol. 2022;134:106189.
    >> Share

  217. LIU W, Ji T, Zhang C, Zhou Q, et al
    Cell-free DNA hypermethylated genes may have a limited role in cancer screening but a potential role in risk assessment of head and neck cancer.
    Oral Oncol. 2022;134:106129.
    >> Share

  218. HENG Y, Yang Z, Lin J, Liu Q, et al
    Risks of central lymph node metastasis in papillary thyroid carcinoma with or without multifocality in at least one lobe: A multi-center analysis.
    Oral Oncol. 2022;134:106185.
    >> Share

    September 2022
  219. MORSE RT, Beaty B, Scanga L, Blumberg J, et al
    Diagnostic accuracy of FNA to determine HPV status in HPV-associated oropharyngeal squamous cell carcinoma.
    Oral Oncol. 2022;134:106131.
    >> Share

  220. ZHU GL, Fang XL, Yang KB, Tang LL, et al
    Development and validation of a joint model for dynamic prediction of overall survival in nasopharyngeal carcinoma based on longitudinal post-treatment plasma cell-free Epstein-Barr virus DNA load.
    Oral Oncol. 2022;134:106140.
    >> Share

  221. XUE F, Ou D, Ou X, Zhou X, et al
    Long-term results of the phase II dose and volume de-escalation trial for locoregionally advanced nasopharyngeal carcinoma.
    Oral Oncol. 2022;134:106139.
    >> Share

  222. SANKAR S
    New insights into CAR T-cell therapy for recurrent head and neck squamous cell carcinoma.
    Oral Oncol. 2022;134:106137.
    >> Share

  223. KMIECIK M, Nogal P, Wierzbicka M, Jackowska J, et al
    Anterolateral thigh free flap reconstruction of pharyngoesophageal defect caused by radiotherapy for laryngeal cancer: A case report.
    Oral Oncol. 2022;134:106135.
    >> Share

  224. GUPTA T, Kannan S, Ghosh-Laskar S, Agarwal JP, et al
    Concurrent chemoradiotherapy with cisplatin given once-a-week versus every-three weekly in head and neck squamous cell carcinoma: Non-inferior, equivalent, or superior?
    Oral Oncol. 2022;134:106130.
    >> Share

  225. HITT R, Mesia R, Lozano A, Iglesias Docampo L, et al
    Randomized phase 3 noninferiority trial of radiotherapy and cisplatin vs radiotherapy and cetuximab after docetaxel-cisplatin-fluorouracil induction chemotherapy in patients with locally advanced unresectable head and neck cancer.
    Oral Oncol. 2022;134:106087.
    >> Share

  226. ZHANG J, Wu HY, Lu Q, Shan XF, et al
    Effects of personalized swallowing rehabilitation in patients with oral cancer after free flap transplantation: A cluster randomized controlled trial.
    Oral Oncol. 2022;134:106097.
    >> Share

  227. PATIL V, Kumar S, Noronha V, Menon N, et al
    Long term outcomes of a randomized controlled clinical trial comparing the efficacy of Cabazitaxel versus docetaxel as second-line or above therapy in recurrent head and neck cancer.
    Oral Oncol. 2022;134:106085.
    >> Share

  228. SARODE GS, Anand R, Sharma NK, Sarode SC, et al
    Hot and cold tumor: Recent developments and perspectives on oral cancer.
    Oral Oncol. 2022;134:106114.
    >> Share

  229. BEOM HEO D, Piao Y, Hee Lee J, Ju SH, et al
    Completion thyroidectomy may not be required for papillary thyroid carcinoma with multifocality, lymphovascular invasion, extrathyroidal extension to the strap muscles, or five or more central lymph node micrometastasis.
    Oral Oncol. 2022;134:106115.
    >> Share

  230. SAHNI V, Kumar A, Gupta S, Sharma S, et al
    Metformin and oral cancer.
    Oral Oncol. 2022;134:106125.
    >> Share

  231. TOBIAS MAS, Nogueira BP, Santana MCS, Pires RG, et al
    Artificial intelligence for oral cancer diagnosis: What are the possibilities?
    Oral Oncol. 2022;134:106117.
    >> Share

  232. SHREE HARINI K, Ezhilarasan D, Elumalai P
    Restoring the anti-tumor property of PTEN: A promising oral cancer treatment.
    Oral Oncol. 2022;134:106113.
    >> Share

  233. NONG T, Medrano T, Marrero C, Rubens M, et al
    Radiation induced taste changes in head and neck cancer - differential impact of treatment factors.
    Oral Oncol. 2022;134:106105.
    >> Share

  234. MUTHUKRISHNAN L
    "TGM3 - A novel biomarker as a potential diagnostic target for head and neck squamous cell carcinoma (HNSCC)".
    Oral Oncol. 2022;134:106118.
    >> Share

  235. MONY U, Priya Veeraraghavan V
    "Rules" to the genetic progression of tumours deciphered: Is it time to think differently in treating oral cancer patients?
    Oral Oncol. 2022;134:106111.
    >> Share

  236. PRASAD M, Jayaraman S, Rajagopal P, Veeraraghavan VP, et al
    Apoptosis regulating CircRNAs: Emerging role in oral cancer therapeutics.
    Oral Oncol. 2022;134:106107.
    >> Share

  237. DE WIT JG, van Schaik JE, Voskuil FJ, Vonk J, et al
    Comparison of narrow band and fluorescence molecular imaging to improve intraoperative tumour margin assessment in oral cancer surgery.
    Oral Oncol. 2022;134:106099.
    >> Share

  238. VILASECA I, Xavier Aviles-Jurado F, Lehrer E, Valduvieco I, et al
    CO2-TOLMS for laryngeal cancer in the elderly, pushing the boundaries of partial laryngectomy.
    Oral Oncol. 2022;134:106088.
    >> Share

  239. YUAN H, Yan M, Liang X, Liu W, et al
    Decoding the associations between cell functional states in head and neck cancer based on single-cell transcriptome.
    Oral Oncol. 2022;134:106110.
    >> Share

  240. BALACHANDER K, Vijayashree Priyadharsini J, Paramasivam A
    Advances in oral cancer early diagnosis and treatment strategies with liquid biopsy-based approaches.
    Oral Oncol. 2022;134:106108.
    >> Share

  241. TAKENAKA Y, Takemoto N, Otsuka T, Nishio M, et al
    Predictive significance of body composition indices in patients with head and neck squamous cell carcinoma treated with nivolumab: A multicenter retrospective study.
    Oral Oncol. 2022;132:106018.
    >> Share

  242. CHABRILLAC E, Jackson R, Mattei P, D'Andrea G, et al
    Paratracheal lymph node dissection during total (pharyngo-)laryngectomy: A systematic review and meta-analysis.
    Oral Oncol. 2022;132:106017.
    >> Share

  243. DENG W, Zhao G, Li Z, Yang L, et al
    Recovery pattern analysis of swallowing function in patients undergoing total glossectomy and hemiglossectomy.
    Oral Oncol. 2022;132:105981.
    >> Share

    August 2022
  244. CHANDRALEKHA SELVAKUMAR S, Auxzilia Preethi K, Sekar D
    Non-coding RNAs influencing anti PD-1 immunotherapy in head and neck squamous cell carcinoma (HNSCC).
    Oral Oncol. 2022;134:106092.
    >> Share

  245. YADALAM PK, Anegundi RV, Ramadoss R, Joseph B, et al
    Felodipine repurposed for targeting TRPV1 receptor to relieve oral cancer pain.
    Oral Oncol. 2022;134:106094.
    >> Share

  246. SEMPRINI J
    Oral cancer screening prevalence in low-income adults before and after the ACA.
    Oral Oncol. 2022;134:106055.
    >> Share

  247. PAZHANI J, Veeraraghavan VP, Jayaraman S
    Aurora kinase in oral cancer: A potential therapeutic target to improve treatment efficiency.
    Oral Oncol. 2022;134:106093.
    >> Share

  248. KRUTZ M, Acharya P, Chissoe G, Raj V, et al
    Tobacco cessation after head and neck cancer diagnosis is an independent predictor of treatment response and long-term survival.
    Oral Oncol. 2022;134:106072.
    >> Share

  249. HEMPENIUS MA, Bisheshar SK, Slagter-Menkema L, van der Kamp MF, et al
    Inter-assay reliability of programmed cell death-ligand 1 in head and neck squamous cell carcinoma.
    Oral Oncol. 2022;134:106086.
    >> Share

  250. VAISH R, Mittal N, Mahajan A, Rane SU, et al
    Sentinel node biopsy in node negative early oral cancers: Solution to the conundrum!
    Oral Oncol. 2022;134:106070.
    >> Share

  251. MUTHUPANDIAN S, Muralidharan M, Madhavan Y, Hariharan NM, et al
    Prospective role of salivary MicroRNA for early detection - personalized therapy of head and neck squamous cell carcinoma.
    Oral Oncol. 2022;134:106063.
    >> Share

  252. PARAMASIVAM A
    Circulating circular RNAs: Novel potential biomarkers and therapeutic targets for oral cancer.
    Oral Oncol. 2022;134:106067.
    >> Share

  253. EZHILARASAN D, Shree Harini K
    Novel mTOR inhibitors: Promising therapeutic interventions in oral cancer therapy.
    Oral Oncol. 2022;133:106066.
    >> Share

  254. PRASAD M, Veeraraghavan VP, Jayaraman S
    Tumorigenic potential of GLUT4: A therapeutic target for head and neck squamous cell carcinoma.
    Oral Oncol. 2022;133:106061.
    >> Share

  255. YU C, Zhou Z
    Relationship between young non-smokers and oral cancer: What can we learn?
    Oral Oncol. 2022;133:106064.
    >> Share

  256. REKHA K, Venkidasamy B, Govindasamy R, Neralla M, et al
    Isothiocyanates (AITC & BITC) bioactive molecules: Therapeutic potential for oral cancer.
    Oral Oncol. 2022;133:106060.
    >> Share

  257. BALACHANDER K, Abilasha R, Priyadharsini JV, Balamurugan R, et al
    Targeting mitochondria for apoptosis in oral cancer: Therapeutic potential and obstacles.
    Oral Oncol. 2022;133:106059.
    >> Share

  258. SARODE GS, Kumari N, Gophane R, Ghone U, et al
    Trends and prospects in oral cancer vaccine.
    Oral Oncol. 2022;133:106051.
    >> Share

  259. MA SJ, Yu H, Khan M, Yu B, et al
    Defining the optimal threshold and prognostic utility of pre-treatment hemoglobin level as a biomarker for survival outcomes in head and neck cancer patients receiving chemoradiation.
    Oral Oncol. 2022;133:106054.
    >> Share

  260. VERDONCK-DE LEEUW I, Dawson C, Licitra L, Eriksen JG, et al
    European Head and Neck Society recommendations for head and neck cancer survivorship care.
    Oral Oncol. 2022;133:106047.
    >> Share

  261. DONA MG, Rollo F, Pichi B, Moretto S, et al
    Updates on Human Papillomavirus-driven oropharyngeal squamous cell carcinomas in a southern European country.
    Oral Oncol. 2022;131:105947.
    >> Share

    July 2022
  262. DASSE R, Dupin C, Gorphe P, Temam S, et al
    Proposal for an algorithm to avoid neck dissection during salvage total laryngectomy. A GETTEC multicentric study.
    Oral Oncol. 2022;133:106026.
    >> Share

  263. CHOW JCH, Lee AWM, Wong CHL, Ng WT, et al
    Epstein-Barr virus directed screening for nasopharyngeal carcinoma in individuals with positive family history: A systematic review.
    Oral Oncol. 2022;133:106031.
    >> Share

  264. KRISHNAN M, Venkidasamy B
    PEITC: A prospective natural metabolite in oral cancer treatment.
    Oral Oncol. 2022;133:106044.
    >> Share

  265. YU C, Zhou Z
    Assessment of oral dysfunction after oral cancer treatment.
    Oral Oncol. 2022;133:106046.
    >> Share

  266. SARODE GS, Sarode SC, Kumari N, Gophane R, et al
    FAP-targeted imaging in oral cancer: Critical viewpoints.
    Oral Oncol. 2022;133:106024.
    >> Share

  267. YASASVE M, Manjusha M, Saravanan M
    Polymorphism in pro-inflammatory cytokines and their genetic susceptibility towards oral precancerous lesions and oral cancer.
    Oral Oncol. 2022;133:106027.
    >> Share

  268. KONO M, Saito S, Egloff AM, Allen CT, et al
    The mouse oral carcinoma (MOC) model: A 10-year retrospective on model development and head and neck cancer investigations.
    Oral Oncol. 2022;132:106012.
    >> Share

  269. MELO G, Silva CAB, Hague A, Parkinson EK, et al
    Anticancer effects of putative and validated BH3-mimetic drugs in head and neck squamous cell carcinomas: An overview of current knowledge.
    Oral Oncol. 2022;132:105979.
    >> Share

  270. KUMARESAN V, Sivaperumal P, Smiline Girija AS
    Bispecific antibodies targeting tumor-associated metalloprotease and recruit NK cells - Multifunctional therapeutic approach against oral cancer.
    Oral Oncol. 2022;132:106013.
    >> Share

  271. HUANG H, Li L, Cao Q, Jiang H, et al
    Choroid plexus papilloma of auditory nerve: A case report.
    Oral Oncol. 2022;132:106009.
    >> Share

  272. RENU K, Veeraraghavan VP, Raj A T, Patil S, et al
    The peroxisome proliferator-activated receptor-alpha (PPAR-alpha): A new therapeutic target for oral cancer.
    Oral Oncol. 2022;132:106007.
    >> Share

  273. ALLEN JL, Hames RA, Mastroianni NM, Greenstein AE, et al
    Evaluation of the matrix metalloproteinase 9 (MMP9) inhibitor Andecaliximab as an Anti-invasive therapeutic in Head and neck squamous cell carcinoma.
    Oral Oncol. 2022;132:106008.
    >> Share

  274. SARODE GS, Kumari N, Sarode SC
    Oral cancer histopathology images and artificial intelligence: A pathologist's perspective.
    Oral Oncol. 2022;132:105999.
    >> Share

  275. DE VRIES J, Poelman A, Sidorenkov G, Festen S, et al
    The association of frailty and outcomes of geriatric assessment with acute radiation-induced toxicity in patients with head and neck cancer.
    Oral Oncol. 2022;130:105933.
    >> Share

  276. RIBEIRO MFA, Oliveira MCM, Leite AC, Bruzinga FFB, et al
    Assessment of screening programs as a strategy for early detection of oral cancer: a systematic review.
    Oral Oncol. 2022;130:105936.
    >> Share

  277. TANG R, Mao S, Liu S, Li Z, et al
    Types of endoscopic surgical approaches for benign parapharyngeal space tumors.
    Oral Oncol. 2022;130:105875.
    >> Share

  278. EZHILARASAN D, Shree Harini K, Lakshmi T
    Osteopontin: A reliable diagnostic marker and an attractive therapeutic target in oral cancers.
    Oral Oncol. 2022;132:106005.
    >> Share

    June 2022
  279. MISRA SR, Das R
    Central oral medicine repository: A proposal to speed up the diagnostic process for oral potentially malignant disorders and oral carcinoma!
    Oral Oncol. 2022;132:105998.
    >> Share

  280. BALACHANDER K, Paramasivam A
    Anti-PD-1 agent: A promising immunotherapy drug for oral cancer?
    Oral Oncol. 2022;132:105997.
    >> Share

  281. BABU S, Krishnan M, Priya Veeraraghavan V, Jayaraman S, et al
    Role of salivary miRNAs in the diagnosis and prognosis of head and neck squamous cell carcinoma.
    Oral Oncol. 2022;132:105993.
    >> Share

  282. ALESSANDRINI L, Ferrari M, Taboni S, Sbaraglia M, et al
    Tumor-stroma ratio, neoangiogenesis and prognosis in laryngeal carcinoma. A pilot study on preoperative biopsies and matched surgical specimens.
    Oral Oncol. 2022;132:105982.
    >> Share

  283. SHREE HARINI K, Ezhilarasan D, Lakshmi T
    Novel fibroblast growth factor receptor inhibitors: Potential therapeutic approach in oral cancer treatment.
    Oral Oncol. 2022;132:105983.
    >> Share

  284. REVATHI D, Dhanraj G, Ashok V
    Immune check point inhibitors: A promising therapeutic approach in oral cancer.
    Oral Oncol. 2022;132:105977.
    >> Share

  285. SEKARAN S, Pitchaiah S, Ganapathy D
    Can miR-21 be considered as a potential biomarker and a therapeutic target in oral cancer?
    Oral Oncol. 2022;131:105973.
    >> Share

  286. ZONG J, Ji P, Lin C, Zhang R, et al
    Plasma Epstein-Barr viral DNA load after completion of two cycles of induction chemotherapy predicts outcomes for patients with advanced-stage nasopharyngeal carcinoma.
    Oral Oncol. 2022;131:105972.
    >> Share

  287. BALACHANDER K, Paramasivam A
    Ferroptosis: An emerging therapeutic target for oral cancer.
    Oral Oncol. 2022;131:105970.
    >> Share

  288. GANAPATHY D, Sekaran S, Pitchaiah S
    Is prognostic monitoring of high-risk populations at risk for oral cancer necessary after infection with COVID-19?
    Oral Oncol. 2022;131:105968.
    >> Share

  289. LUO HD, Xia FJ, Wu JH, Yi B, et al
    Efficacy of chemoradiotherapy in survival of stage nasopharyngeal carcinoma and establishment of a prognostic model.
    Oral Oncol. 2022;131:105927.
    >> Share

  290. SHREE HARINI K, Ezhilarasan D, Lakshmi T
    Patient derived tumour organoids: An emerging strategy in oral cancer research and therapeutics.
    Oral Oncol. 2022;131:105954.
    >> Share

  291. VARGHESE BT, Nair SP, Janardhan D
    Transglottic intralaryngeal papillary thyroid carcinoma.
    Oral Oncol. 2022;131:105935.
    >> Share

  292. YANG Z, Liao J, Schumaker L, Carter-Cooper B, et al
    Simultaneously targeting ErbB family kinases and PI3K in HPV-positive head and neck squamous cell carcinoma.
    Oral Oncol. 2022;131:105939.
    >> Share

  293. SHREE HARINI K, Ezhilarasan D
    Promising autophagy inhibitors: Therapeutic implications in oral cancer.
    Oral Oncol. 2022;131:105948.
    >> Share

  294. DE FELICE F
    FLASH radiotherapy in head and neck cancer: Myth or reality?
    Oral Oncol. 2022;131:105953.
    >> Share

  295. FERRELI F, Pirola F, Di Santo D, De Virgilio A, et al
    A critical analysis of the classifications of squamous cell carcinoma of the nasal vestibule.
    Oral Oncol. 2022;129:105880.
    >> Share

    May 2022
  296. JAYARAMAN S, Pazhani J, PriyaVeeraraghavan V, Raj AT, et al
    PCNA and Ki67: Prognostic proliferation markers for oral cancer.
    Oral Oncol. 2022;130:105943.
    >> Share

  297. BALACHANDER K, Paramasivam A
    Selective autophagy as a potential therapeutic target for oral cancer.
    Oral Oncol. 2022;130:105934.
    >> Share

  298. PATIL VM, Kolkur M, Kumar Chinthala S, Waratkar G, et al
    Long term toxicity and tolerance of concurrent docetaxel with radiotherapy in cisplatin-ineligible head and neck cancer patients.
    Oral Oncol. 2022;130:105908.
    >> Share

  299. UEDA Y, Okano S, Enokida T, Fujisawa T, et al
    Nivolumab for recurrent or metastatic head and neck cancer patients with non-squamous cell carcinoma and/or a primary subsite excluded from CheckMate141, a retrospective study.
    Oral Oncol. 2022;130:105932.
    >> Share

  300. WARNER L, O'Hara JT, Lin DJ, Oozeer N, et al
    Transoral robotic surgery and neck dissection alone for head and neck squamous cell carcinoma: Influence of resection margins on oncological outcomes.
    Oral Oncol. 2022;130:105909.
    >> Share

  301. VARGHESE BT, Shivanesan P
    Anatomical distortion of the right recurrent laryngeal nerve in level 7 neck dissection.
    Oral Oncol. 2022;130:105929.
    >> Share

  302. SMILINE GIRIJA AS
    Natural "epidrugs" and the need of basket trials in the treatment of oral cancer in India.
    Oral Oncol. 2022;130:105931.
    >> Share

  303. SHIAO JC, Holt D, Ladbury C, Gao D, et al
    The role of concomitant chemoradiotherapy versus radiation alone in T1-3N0 HPV-positive and HPV-negative oropharyngeal squamous cell carcinoma.
    Oral Oncol. 2022;130:105907.
    >> Share

  304. LOW SK, Reed CT, Millo C, Turkbey EB, et al
    Cecal mass: An unusual site of metastasis from HPV-associated oropharyngeal cancer.
    Oral Oncol. 2022;130:105928.
    >> Share

  305. PARAMASIVAM A
    Plasma circulating tumor DNA as a molecular marker for oral cancer.
    Oral Oncol. 2022;130:105926.
    >> Share

  306. SELVARAJ J, Yasothkumar D, Vishnu Priya V, Raj AT, et al
    Development and tumorigenic potential of TP53: A therapeutic target for head and neck squamous cell carcinoma.
    Oral Oncol. 2022;130:105922.
    >> Share

  307. YANG X, Song H, Ji T, Du G, et al
    The implications of gene mutations in salivary DNA for noninvasive diagnosis of head and neck cancer with a focus on oral cancer.
    Oral Oncol. 2022;130:105924.
    >> Share

  308. FORNER D, Mok F, Verma N, Karam I, et al
    Placement technique impacts gastrostomy tube-related complications amongst head and neck cancer patients.
    Oral Oncol. 2022;130:105903.
    >> Share

  309. PAZHANI J, Jayaraman S, Veeraraghavan VP, Somasundaram DB, et al
    Targeting cancer associated fibroblasts - A TGF-beta based immunotherapy for head and neck squamous cell carcinoma.
    Oral Oncol. 2022;130:105899.
    >> Share

  310. JIANG Y, Yang S, Qi Y
    Comment on: The prognostic value of radiologic extranodal extension in nasopharyngeal carcinoma: Systematic review and meta-analysis.
    Oral Oncol. 2022;130:105872.
    >> Share

  311. MADY LJ, Baddour K, Hodges JC, Magana LC, et al
    Corrigendum to "The impact of frailty on mortality in non-surgical head and neck cancer treatment: Shifting the clinical paradigm" [Oral Oncol. 126 (2022) 105766].
    Oral Oncol. 2022 May 2:105882. doi: 10.1016/j.oraloncology.2022.105882.
    >> Share

  312. SWARTZ JE, Smits HJG, Philippens MEP, de Bree R, et al
    Correlation and colocalization of HIF-1alpha and pimonidazole staining for hypoxia in laryngeal squamous cell carcinomas: A digital, single-cell-based analysis.
    Oral Oncol. 2022;128:105862.
    >> Share

  313. YEOM S, Jung EK, Lee DH, Lee JK, et al
    Clinical features and recurrence factors of benign neoplasms of the tongue base.
    Oral Oncol. 2022;128:105866.
    >> Share

  314. MULLER RG, Hamill CS, Vu B, Thuener J, et al
    Impact of AJCC 8th edition staging system and definitive treatment choice on the prognosis of complete responders with p16+ and p16- oropharyngeal squamous cell carcinomas.
    Oral Oncol. 2022;128:105861.
    >> Share

    April 2022
  315. GALLOGLY JA JR, Weber AK, Mazul AL, Brinkmeier JV, et al
    Inferior outcomes associated with emergency department presentation for head and neck cancer surgery.
    Oral Oncol. 2022;129:105894.
    >> Share

  316. SHE L, Tian K, Han J, Zuo W, et al
    Pembrolizumab with or without chemotherapy versus cetuximab plus chemotherapy to treat recurrent or metastatic head and neck squamous cell carcinoma: An updated KEYNOTE-048 based cost-effectiveness analysis.
    Oral Oncol. 2022;129:105871.
    >> Share

  317. KATO A, Matsuda Y, Morioka R, Okui T, et al
    Discrepancy between subjective and objective postoperative oral dysfunction assessment after oral cancer treatment: A single-center cross-sectional study.
    Oral Oncol. 2022;129:105879.
    >> Share

  318. HAIST C, Poschinski Z, Bister A, Hoffmann MJ, et al
    Engineering a single-chain variable fragment of cetuximab for CAR T-cell therapy against head and neck squamous cell carcinomas.
    Oral Oncol. 2022;129:105867.
    >> Share

  319. SEKAR D, Panagal M, Manimaran D, Ahmad N, et al
    miR-185 and its anti-miR as a biomarker and therapeutic target for oral cancer.
    Oral Oncol. 2022;129:105873.
    >> Share

  320. LIU T, Ma L, Song L, Yan B, et al
    CENPM upregulation by E5 oncoprotein of human papillomavirus promotes radiosensitivity in head and neck squamous cell carcinoma.
    Oral Oncol. 2022;129:105858.
    >> Share

  321. NERALLA M, Senthilnthan P, Kubendiran D, Nandan A, et al
    Dry needle therapy for post operative shoulder dysfunction in oral cancer patients.
    Oral Oncol. 2022;128:105865.
    >> Share

  322. PETRELLI F, Trevisan F, Ghidini A, Capriotti V, et al
    Comparison of platinum-based regimens in combination with radiotherapy for head and neck cancers: A network meta-analysis.
    Oral Oncol. 2022;128:105864.
    >> Share

  323. ZHOU S, Chan C, Rulach R, Dyab H, et al
    Long term survival in patients with human papillomavirus-positive oropharyngeal cancer and equivocal response on 12-week PET-CT is not compromised by the omission of neck dissection.
    Oral Oncol. 2022;128:105870.
    >> Share

  324. YANG ZC, Nie ZQ, Chen QY, Du CC, et al
    Cost-Effectiveness analysis of combining plasma Epstein-Barr virus DNA testing and different surveillance imaging modalities for nasopharyngeal carcinoma patients in first remission.
    Oral Oncol. 2022;128:105851.
    >> Share

  325. FENG G, Feng H, Qi Y, Wang T, et al
    Interaction analysis between germline genetic variants and somatic mutations in head and neck cancer.
    Oral Oncol. 2022;128:105859.
    >> Share

  326. CHEN Y, Zheng X, Lin J, Gao X, et al
    A high homologous recombination deficiency score is associated with poor survival and a non-inflamed tumor microenvironment in head and neck squamous cell carcinoma patients.
    Oral Oncol. 2022;128:105860.
    >> Share

  327. TIAN K, Han J, Wang Z, Chen J, et al
    Immune checkpoint inhibition in first-line treatment for recurrent or metastatic nasopharyngeal carcinoma: A CAPTAIN-1st and JUPITER-02 trial-based cost-effectiveness analysis.
    Oral Oncol. 2022;128:105842.
    >> Share

  328. BALACHANDER K, Roy A, Priyadharsini JV, Murugan S, et al
    Mitochondrial DNA in circulating exosomes: A novel biomarker and potential therapeutic target for oral cancer.
    Oral Oncol. 2022;128:105857.
    >> Share

  329. DE LA COUR CD, Munk C, Aalborg GL, Kjaer SK, et al
    Base of tongue/tonsillar and laryngeal cancer in Denmark 1994-2018: Temporal trends in incidence according to education and age.
    Oral Oncol. 2022;128:105832.
    >> Share

  330. BANERJEE A, Misra SR, Roy B, Singh S, et al
    Central oral histopathology registry (COHR) - A proposal promising hope for oral cancer and oral pathology research.
    Oral Oncol. 2022;128:105856.
    >> Share

  331. SEKAR D, Murthykumar K, Ganapathy D
    miR-206 and its mimics: A predictive biomarker and therapeutic molecule in the treatment of oral cancer.
    Oral Oncol. 2022;128:105849.
    >> Share

  332. RISCHIN D, Harrington KJ, Greil R, Soulieres D, et al
    Pembrolizumab alone or with chemotherapy for recurrent or metastatic head and neck squamous cell carcinoma: Health-related quality-of-life results from KEYNOTE-048.
    Oral Oncol. 2022;128:105815.
    >> Share

  333. TANS L, Al-Mamgani A, Kwa SLS, Elbers JBW, et al
    Single vocal cord irradiation for early-stage glottic cancer: Excellent local control and favorable toxicity profile.
    Oral Oncol. 2022;127:105782.
    >> Share

  334. DODDAWAD VG, Premalatha BR, Sreeshyla HS, Nitin P, et al
    Classification staging systems on clinical and radiographic features of inverted sinonasal papilloma: A case report.
    Oral Oncol. 2022;127:105768.
    >> Share

    March 2022
  335. PATIL V, Noronha V, Joshi A, Menon N, et al
    RMAC study: A randomized study for evaluation of metronomic adjuvant chemotherapy in recurrent head and neck cancers post salvage surgical resection in those who are ineligible for re-irradiation.
    Oral Oncol. 2022;128:105816.
    >> Share

  336. CHANG CT, Liu SP, Muo CH, Liao YF, et al
    The impact of dental therapy timelines and irradiation dosages on osteoradionecrosis in oral cancer patients: A population-based cohort study.
    Oral Oncol. 2022;128:105827.
    >> Share

  337. HSIEH MC, Wang CC, Yang CC, Lien CF, et al
    The role of induction chemotherapy in patients with locally advanced head and neck squamous cell carcinoma: A nationwide population-based matched study.
    Oral Oncol. 2022;128:105848.
    >> Share

  338. YANG X, Xu X, Zhang C, Ji T, et al
    The diagnostic value and prospects of gene mutations in circulating tumor DNA for head and neck cancer monitoring.
    Oral Oncol. 2022;128:105846.
    >> Share

  339. RANJAN MISRA S, Das R
    Tele-screening for early detection of oral cancer during the COVID-19 pandemic era: Diagnostic pitfalls and potential misinterpretations!
    Oral Oncol. 2022;128:105845.
    >> Share

  340. MATTOX AK, D'Souza G, Khan Z, Allen H, et al
    Comparison of next generation sequencing, droplet digital PCR, and quantitative real-time PCR for the earlier detection and quantification of HPV in HPV-positive oropharyngeal cancer.
    Oral Oncol. 2022;128:105805.
    >> Share

  341. BALACHANDER K, Paramasivam A
    Cell-free mitochondrial DNA as a novel non-invasive biomarker for oral cancer.
    Oral Oncol. 2022;127:105825.
    >> Share

  342. YAMAGUMA Y, Kaneuji T, Shirouzu S, Fukui T, et al
    Combination therapy of Mohs paste and chemotherapy improved metastatic oral cancer to the precordium skin and bilateral axillary lymph nodes: A case report.
    Oral Oncol. 2022;127:105817.
    >> Share

  343. VILLARD A, Breuskin I, Casiraghi O, Asmandar S, et al
    Confocal laser endomicroscopy and confocal microscopy for head and neck cancer imaging: Recent updates and future perspectives.
    Oral Oncol. 2022;127:105826.
    >> Share

  344. PATIL V, Alone M, Rai R, Noronha V, et al
    Safety and efficacy of pembrolizumab with chemotherapy in locally advanced head and neck cancers.
    Oral Oncol. 2022;127:105824.
    >> Share

  345. DE LUCA P, Di Stadio A, Tassone D, de Campora L, et al
    Large cervical mass and head and neck cancer. First report of ectopic papillary adenoma of the lung.
    Oral Oncol. 2022;127:105823.
    >> Share

  346. DEVARAJA K, Kabekkodu SP
    Oral microbiome; a potential game-changer in the management of oral cancer?
    Oral Oncol. 2022;127:105822.
    >> Share

  347. BONETTI VALENTE V, Mantovan Mazzon B, Urbano Collado F, Conrado Neto S, et al
    Clinicopathological and prognostic profile of non-smoking and non-drinking head and neck cancer patients: a population-based comparative study.
    Oral Oncol. 2022;127:105799.
    >> Share

  348. SHETH S, Gilbert J, Deal AM, Chera B, et al
    Mature follow up of induction chemotherapy with carboplatin, nab-paclitaxel, cetuximab in head and neck squamous cell carcinoma.
    Oral Oncol. 2022;127:105807.
    >> Share

  349. VALERO C, Yuan A, Zanoni DK, Lei E, et al
    Young non-smokers with oral cancer: What are we missing and why?
    Oral Oncol. 2022;127:105803.
    >> Share

  350. ELUMALAI P, Ezhilarasan D, Lakshmi T
    Targeting head and neck cancer epigenetics with CRISPR-dCas9: An emerging therapeutic approach.
    Oral Oncol. 2022;127:105801.
    >> Share

  351. GLAZAR DJ, Johnson M, Farinhas J, Steuer CE, et al
    Early response dynamics predict treatment failure in patients with recurrent and/or metastatic head and neck squamous cell carcinoma treated with cetuximab and nivolumab.
    Oral Oncol. 2022;127:105787.
    >> Share

  352. ROUTILA J, Qiao X, Weltner J, Rantala JK, et al
    Cisplatin overcomes radiotherapy resistance in OCT4-expressing head and neck squamous cell carcinoma.
    Oral Oncol. 2022;127:105772.
    >> Share

  353. BRODY RM, Shimunov D, Cohen RB, Lin A, et al
    A benchmark for oncologic outcomes and model for lethal recurrence risk after transoral robotic resection of HPV-related oropharyngeal cancers.
    Oral Oncol. 2022;127:105798.
    >> Share

  354. GONCALVES JM, Scarini JF, Gondak R, Altemani A, et al
    Oral involvement of sinonasal undifferentiated carcinoma: A case report and immunohistochemical study of a challenging case.
    Oral Oncol. 2022;126:105779.
    >> Share

  355. SAKTHIVEL P, Raveendran S, Rajeshwari M
    Sinonasal small round blue cell tumors: What the clinician must know!
    Oral Oncol. 2022;126:105735.
    >> Share

  356. PETRIDES GA, Dunn M, Charters E, Venchiarutti R, et al
    Health-related quality of life in maxillectomy patients undergoing dentoalveolar rehabilitation.
    Oral Oncol. 2022;126:105757.
    >> Share

    February 2022
  357. QURESHI HA, Zhu X, Yang GH, Steadele M, et al
    Impact of HPV status on immune responses in head and neck squamous cell carcinoma.
    Oral Oncol. 2022;127:105774.
    >> Share

  358. BELGIOIA L, Becherini C, Bacigalupo A, Bonomo P, et al
    Chemo- immunotherapy and radiation in locally advanced head and neck cancer: Where do we stand?
    Oral Oncol. 2022;127:105773.
    >> Share

  359. DAGLINAMRATA, Lakshmi T, Rushabh D, Dineshkumar T, et al
    Telescreening as an alternate modality for early detection of oral cancer.
    Oral Oncol. 2022;127:105785.
    >> Share

  360. HARING CT, Dermody SM, Yalamanchi P, Kang SY, et al
    The future of circulating tumor DNA as a biomarker in HPV related oropharyngeal squamous cell carcinoma.
    Oral Oncol. 2022;126:105776.
    >> Share

  361. MICHMERHUIZEN NL, Heenan C, Wang J, Leonard E, et al
    Combined Pik3ca-H1047R and loss-of-function Notch1 alleles decrease survival time in a 4-nitroquinoline N-oxide-driven head and neck squamous cell carcinoma model.
    Oral Oncol. 2022;126:105770.
    >> Share

  362. MADY LJ, Baddour K, Hodges JC, Magana LC, et al
    The impact of frailty on mortality in non-surgical head and neck cancer treatment: Shifting the clinical paradigm.
    Oral Oncol. 2022;126:105766.
    >> Share

  363. ZHANG S, Zhang W, Zhang J
    Comprehensive analysis of immune cell infiltration and significant genes in head and neck squamous cell carcinoma.
    Oral Oncol. 2022;126:105755.
    >> Share

  364. LI JL, Hsieh TL, Ou MC, Lin FC, et al
    Prognostic value of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio during immune checkpoint inhibitor treatment in recurrent or metastatic head and neck squamous cell carcinoma patients.
    Oral Oncol. 2022;126:105729.
    >> Share

  365. LENOCI D, Carenzo A, Cavalieri S, Pistore F, et al
    Biological properties of hypoxia-related gene expression models/signatures on clinical benefit of anti-EGFR treatment in two head and neck cancer window-of-opportunity trials.
    Oral Oncol. 2022;126:105756.
    >> Share

  366. CHAN SK, Lin C, Huang SH, Chau TC, et al
    Refining TNM-8 M1 categories with anatomic subgroups for previously untreated de novo metastatic nasopharyngeal carcinoma.
    Oral Oncol. 2022;126:105736.
    >> Share

  367. SILVERMAN DA, Parikh AS, Liu K, Zhan KY, et al
    Predictors of survival following carotid blowout syndrome.
    Oral Oncol. 2022;125:105723.
    >> Share

  368. CHIN O, Alshafai L, O'Sullivan B, Su J, et al
    Inter-rater concordance and operating definitions of radiologic nodal feature assessment in human papillomavirus-positive oropharyngeal carcinoma.
    Oral Oncol. 2022;125:105716.
    >> Share

  369. CHEN TC, Wang C, Su LY, Lin MC, et al
    Impact of invasion into cervical esophagus for patients with hypopharyngeal squamous cell carcinoma.
    Oral Oncol. 2022;125:105683.
    >> Share

    January 2022
  370. SENGUPTA N, Sarode SC, Sarode GS, Ghone U, et al
    Scarcity of publicly available oral cancer image datasets for machine learning research.
    Oral Oncol. 2022;126:105737.
    >> Share

  371. JONAS H, Simnica D, Bussmann L, Zech H, et al
    Early relapse detection by monitoring of circulating cell-free DNA in patients with localized head and neck squamous cell carcinoma: A subgroup analysis of the multicenter randomized clinical trial IMSTAR-HN.
    Oral Oncol. 2022;126:105733.
    >> Share

  372. SEKAR D
    Inhibition of OSCC derived ExomiRs and its therapeutic applications in oral cancer.
    Oral Oncol. 2022;126:105747.
    >> Share

  373. FERRAZZO KL
    Regarding: "Clinical practice guidelines for dental management prior to radiation for head and neck cancer".
    Oral Oncol. 2022;126:105731.
    >> Share

  374. WARD MC, Miller JA, Walker GV, Moeller BJ, et al
    The economic impact of circulating tumor-tissue modified HPV DNA for the post-treatment surveillance of HPV-driven oropharyngeal cancer: A simulation.
    Oral Oncol. 2022;126:105721.
    >> Share

  375. LIU X, Li WF, Ding C, Chen L, et al
    Differential benefit of induction chemotherapy according to body mass index in nasopharyngeal carcinoma - Pooled analysis of two randomized trials.
    Oral Oncol. 2022;125:105718.
    >> Share

  376. K AP, Selvakumar SC, Selvaraj J, Mony U, et al
    Reviewing the potential application of miR-21 inhibitors in oral cancer therapeutics.
    Oral Oncol. 2022;125:105713.
    >> Share

  377. ECONOMOPOULOU P, Kotsantis I, Psyrri A
    Radiotherapy and immunotherapy combination in head and neck cancer: Does current failure qualify as an ending or is it a key to future success?
    Oral Oncol. 2022 Jan 13:105717. doi: 10.1016/j.oraloncology.2022.105717.
    >> Share

  378. CARDIN GB, Bernard M, Bourbonnais J, Bahig H, et al
    The rs6942067 genotype is associated with a worse overall survival in young or non-smoking HPV-negative patients with positive nodal status in head and neck squamous cell carcinoma.
    Oral Oncol. 2022;125:105696.
    >> Share

  379. GILLIGAN G, Piemonte E, Lazos J, Panico R, et al
    Chronic wounds of traumatic origin and oral cancer arising de novo: A potential association?
    Oral Oncol. 2022;125:105711.
    >> Share

  380. PATIL V, Ghandade N, Noronha V, Menon N, et al
    Hypomagnesemia in patients with locally advanced head and neck cancer treated weekly cisplatin-incidence and impact on outcomes.
    Oral Oncol. 2022;125:105709.
    >> Share

  381. VIITASALO S, Karhemo PR, Vaananen J, Ilmarinen T, et al
    Exome sequencing reveals candidate mutations implicated in sinonasal carcinoma and malignant transformation of sinonasal inverted papilloma.
    Oral Oncol. 2022;124:105663.
    >> Share

  382. SAKTHIVEL P, Thakar A, Fernandez-Fernandez MM, Panda S, et al
    TransOral UltraSonic surgery (TOUSS) for oral cavity, oropharyngeal and supraglottic malignancy: A prospective study of feasibility, safety, margins, functional and survival outcomes.
    Oral Oncol. 2022;124:105643.
    >> Share

  383. LI MM, Mroz EA, Faquin WC, Lott-Limbach A, et al
    ERalpha: A biomarker and treatment target for oropharyngeal cancer?
    Oral Oncol. 2022;124:105637.
    >> Share

  384. MALIK A, Panda S, Sakthivel P
    Treatment of early glottic carcinoma: Is it a paradox of choices?
    Oral Oncol. 2022;124:105516.
    >> Share

  385. ZHANG L, Chen L, Xiao M, Xie X, et al
    Locally advanced undifferentiated sarcomatoid carcinoma of the right maxillary sinus with PDCD6-TERT fusion: A rare case report.
    Oral Oncol. 2022;124:105466.
    >> Share

    December 2021
  386. COHEN O, Brauer PR, Judson BL, Burtness BA, et al
    Guideline - Adherence in advanced stage head and neck cancer is associated with improved survival - A National study.
    Oral Oncol. 2021;125:105694.
    >> Share

  387. WANG J, Tian Y, Huang H, Huang D, et al
    The prognosis of HPV-associated metastatic pharyngeal patients by primary and distant site.
    Oral Oncol. 2021;125:105675.
    >> Share

  388. SUBASH A, Bylapudi B, Thakur S, Rao VUS, et al
    Oral cancer in India, a growing problem: Is limiting the exposure to avoidable risk factors the only way to reduce the disease burden?
    Oral Oncol. 2021;125:105677.
    >> Share

  389. MERCHANT YP, Mohan M, Shetty S, Bandemegal M, et al
    The submandibular gland in neck dissection: A necessary casualty or a hapless victim?
    Oral Oncol. 2021;125:105678.
    >> Share

  390. HERNDON P, Jassal JS, Cramer JD
    Association between E-cigarette use and oral HPV-16 infection.
    Oral Oncol. 2021;125:105676.
    >> Share

  391. DOU Y, Ma C, Wang K, Liu S, et al
    Dysbiotic tumor microbiota associates with head and neck squamous cell carcinoma outcomes.
    Oral Oncol. 2021;124:105657.
    >> Share

  392. NOJI R, Kano Y, Hirai H, Onishi I, et al
    MYC-PDL1 axis reduces sensitivity to nivolumab in recurrent head and neck squamous cell carcinoma.
    Oral Oncol. 2021;124:105666.
    >> Share

  393. WEI LY, Lin HC, Tsai FC, Ko JY, et al
    Effects of Interleukin-6 on STAT3-regulated signaling in oral cancer and as a prognosticator of patient survival.
    Oral Oncol. 2021;124:105665.
    >> Share

  394. SARI SY, Yilmaz MT, Aktas BY, Aksoy S, et al
    Results of concurrent radiotherapy and immunotherapy in recurrent and metastatic head and neck cancer: A single-center experience.
    Oral Oncol. 2021;124:105658.
    >> Share

  395. CRAMER JD, Grauer J
    Modeling oral cancer screening in the United States population.
    Oral Oncol. 2021;124:105656.
    >> Share

  396. BIGELOW EO, Windon MJ, Fakhry C, Kiess AP, et al
    Development of a web-based, patient-centered decision aid for oropharyngeal cancer treatment.
    Oral Oncol. 2021;123:105618.
    >> Share

  397. BURNINGHAM K, Moore W, Moon D, Avkshtol V, et al
    Prognostic impact of matted lymphadenopathy in patients with oropharyngeal squamous cell carcinoma treated with definitive chemoradiotherapy.
    Oral Oncol. 2021;123:105623.
    >> Share

    November 2021
  398. GUPTA T, Maheshwari G, Kannan S, Nair S, et al
    Systematic review and meta-analysis of randomized controlled trials comparing elective neck dissection versus sentinel lymph node biopsy in early-stage clinically node-negative oral and/or oropharyngeal squamous cell carcinoma: Evidence-base for pract
    Oral Oncol. 2021;124:105642.
    >> Share

  399. CHAUHAN A, Kaur R, Ghoshal S, Chatterjee D, et al
    Potential prognostic and predictive role of baseline circulating tumor cells in head and neck squamous cell carcinoma.
    Oral Oncol. 2021;124:105636.
    >> Share

  400. FUEREDER T, Minichsdorfer C, Mittlboeck M, Wagner C, et al
    Pembrolizumab plus docetaxel for the treatment of recurrent/metastatic head and neck cancer: A prospective phase I/II study.
    Oral Oncol. 2021;124:105634.
    >> Share

  401. DENARO N, Merlano M, Garrone O
    In reply to immune desert in head and neck squamous cell carcinoma: A review of challenges and opportunities for modulating the tumor immune microenvironment.
    Oral Oncol. 2021;124:105640.
    >> Share

  402. THADURI A, Dungala D, Panuganti A, Majumdar KS, et al
    Addressing the challenges of head and neck cancer care in India - A compelling need of the hour.
    Oral Oncol. 2021;124:105638.
    >> Share

  403. MADHULAXMI M, Abhinav RP
    Protein changes of WNT signaling pathway in oral cancer.
    Oral Oncol. 2021;123:105624.
    >> Share

  404. KOWALCHUK RO, Van Abel KM, Yin LX, Garcia J, et al
    Correlation between radiographic and pathologic lymph node involvement and extranodal extension via CT and PET in HPV-associated oropharyngeal cancer.
    Oral Oncol. 2021;123:105625.
    >> Share

  405. GAU M, Fonseca A, Ozsahin M, Fayette J, et al
    Prognostic impact of extranodal extension in resected head and neck squamous cell carcinomas in the era of postoperative chemoradiation: A retrospective monocentric study.
    Oral Oncol. 2021;123:105605.
    >> Share

  406. MISHRA S, Subash A, Rao VUS, Thakur S, et al
    Role of neoadjuvant chemotherapy in head and neck cancer management: A case for exploring diverse treatment strategies for evaluating long-term efficacy.
    Oral Oncol. 2021;123:105594.
    >> Share

  407. GOLUSINSKI P, Corry J, Poorten VV, Simo R, et al
    De-escalation studies in HPV-positive oropharyngeal cancer: How should we proceed?
    Oral Oncol. 2021;123:105620.
    >> Share

  408. WATSON E, Dorna Mojdami Z, Oladega A, Hope A, et al
    Clinical practice guidelines for dental management prior to radiation for head and neck cancer.
    Oral Oncol. 2021;123:105604.
    >> Share

  409. BRIL SI, Chargi N, Wendrich AW, Wegner I, et al
    Validation of skeletal muscle mass assessment at the level of the third cervical vertebra in patients with head and neck cancer.
    Oral Oncol. 2021;123:105617.
    >> Share

  410. WANG Y, Gao Y, Yuan L, Zhang J, et al
    Psychological needs and associated factors among perioperative patients with oral cancer.
    Oral Oncol. 2021;123:105615.
    >> Share

  411. GRONLUND MP, Jakobsen KK, Mirian C, Gronhoj C, et al
    Nasopharyngeal malignancies in Denmark diagnosed from 1980 to 2014.
    Oral Oncol. 2021;122:105583.
    >> Share

  412. YU J, Tsay C, Sasaki C, Son YH, et al
    Brachytherapy and non-cancer mortality in patients with oral cavity and oropharynx SCCs.
    Oral Oncol. 2021;122:105585.
    >> Share

  413. SEE A, Chu C, Kiong KL, Teo C, et al
    Surgical salvage of recurrent nasopharyngeal cancer- a multi-institutional review.
    Oral Oncol. 2021;122:105556.
    >> Share

  414. SAKTHIVEL P, Ramanikanth TV, Thakar A, Singh CA, et al
    TransOral UltraSonic Surgery (TOUSS) assisted supraglottic laryngectomy: Expanding the spectrum of endoscopic head and neck surgeries.
    Oral Oncol. 2021;122:105562.
    >> Share

  415. THAKAR A, Sakthivel P, Sikka K
    TransOral UltraSonic Surgery (TOUSS) and TransOral Laser (TOL) assisted supraglottic laryngectomy (TOUSS-TOL-SGL): Improvising techniques within the transoral corridor.
    Oral Oncol. 2021;122:105573.
    >> Share

  416. LIN N, Gao J, Wang H, Zhang H, et al
    Diagnostic value of indocyanine green for sentinel lymph node mapping and lymph node metastasis in oral/oropharyngeal carcinoma.
    Oral Oncol. 2021;122:105563.
    >> Share

  417. RE M, Tomasetti M, Monaco F, Amati M, et al
    NGS-based miRNome identifies miR-449 cluster as marker of malignant transformation of sinonasal inverted papilloma.
    Oral Oncol. 2021;122:105554.
    >> Share

  418. MCDOWELL L, Casswell G, Bressel M, Drosdowsky A, et al
    Symptom burden, quality of life, functioning and emotional distress in survivors of human papillomavirus associated oropharyngeal cancer: An Australian cohort.
    Oral Oncol. 2021;122:105560.
    >> Share

  419. MIN PARK Y, Yol Lim J, Woo Koh Y, Kim SH, et al
    Prediction of treatment outcome using MRI radiomics and machine learning in oropharyngeal cancer patients after surgical treatment.
    Oral Oncol. 2021;122:105559.
    >> Share

    October 2021
  420. GEORGE A, Saseendran A, Joseph ST, Gopal KR, et al
    Submandibular gland - The victim of neck dissection.
    Oral Oncol. 2021;123:105591.
    >> Share

  421. CABEZAS-CAMARERO S, Alonso-Ovies A, Merino-Menendez S, Cabrera-Martin MN, et al
    Major pathological response and durable locoregional control after neoadjuvant pembrolizumab-carboplatin-paclitaxel in head and neck cancer.
    Oral Oncol. 2021;123:105589.
    >> Share

  422. BRUIJNEN CP, de Groot LGR, Vondeling AM, de Bree R, et al
    Functional decline after surgery in older patients with head and neck cancer.
    Oral Oncol. 2021;123:105584.
    >> Share

  423. PUTHIYOTTIL IV, Subash A, Thakur S, Rao VUS, et al
    Elective neck dissection versus sentinel node biopsy in early oral cavity cancer - Are we ready for transition?
    Oral Oncol. 2021;123:105597.
    >> Share

  424. SHINN JR, Carey RM, Mady LJ, Shimunov D, et al
    Sex-based differences in outcomes among surgically treated patients with HPV-related oropharyngeal squamous cell carcinoma.
    Oral Oncol. 2021;123:105570.
    >> Share

  425. JOSE MARTELLI A, Assis Machado R, Medeiros Pereira W, Balduino Guimaraes Santos F, et al
    Revaluation of the treatment of head and neck cancer in Brazil during the COVID-19 pandemic - phase 2.
    Oral Oncol. 2021;123:105600.
    >> Share

  426. YUWANATI M, Sarode SC, Gadbail A, Gondivkar S, et al
    Alcohol attributed Oral Cancer and Oral microbiome: Emerging yet neglected research domain.
    Oral Oncol. 2021;123:105596.
    >> Share

  427. YU ST, Ge JN, Sun BH, Wei ZG, et al
    Lymph node yield in the initial central neck dissection (CND) associated with the risk of recurrence in papillary thyroid cancer: A reoperative CND cohort study.
    Oral Oncol. 2021;123:105567.
    >> Share

  428. SHU L, Wang D, Nannapaneni S, Sun Y, et al
    Tipifarnib enhances anti-EGFR activity of cetuximab in non-HRas mutated head and neck squamous cell carcinoma cancer (HNSCC).
    Oral Oncol. 2021;122:105546.
    >> Share

  429. MA D, Orner D, Ghaly MM, Parashar B, et al
    Automated health chats for symptom management of head and neck cancer patients undergoing radiation therapy.
    Oral Oncol. 2021;122:105551.
    >> Share

  430. ZHAO Y, Li WF, Li QJ, He SW, et al
    WIPI-1 inhibits metastasis and tumour growth via the WIPI-1-TRIM21 axis and MYC regulation in nasopharyngeal carcinoma.
    Oral Oncol. 2021;122:105576.
    >> Share

  431. ROSENBERG AJ, Agrawal N, Pearson A, Gooi Z, et al
    Risk and response adapted de-intensified treatment for HPV-associated oropharyngeal cancer: Optima paradigm expanded experience.
    Oral Oncol. 2021;122:105566.
    >> Share

  432. TSENG WH, Li TH, Chiu HL, Yang TL, et al
    Long-term swallowing-related outcomes in oral cancer patients receiving proactive swallowing therapy.
    Oral Oncol. 2021;122:105569.
    >> Share

  433. BRIL SI, van Beers MA, Chargi N, Carrillo Minulina N, et al
    Skeletal muscle mass at C3 is a strong predictor for skeletal muscle mass at L3 in sarcopenic and non-sarcopenic patients with head and neck cancer.
    Oral Oncol. 2021;122:105558.
    >> Share

  434. PENG H, Chen L, Mao YP, Tian L, et al
    Nomogram-aided individual induction chemotherapy regimen selection in advanced nasopharyngeal carcinoma.
    Oral Oncol. 2021;122:105555.
    >> Share

  435. CARNEVALE C, Pagan-Pomar A, Bianchi A, Sarria-Echegaray P, et al
    Right colonic interposition for severe pharyngoesophageal stricture in head and neck patients: A feasible rescue strategy after multiple failed reconstructive options.
    Oral Oncol. 2021;121:105481.
    >> Share

  436. HANS S, Chebib E, Chekkoury-Idrissi Y, Distinguin L, et al
    Surgical and oncological outcomes of transoral robotic total laryngectomy: A case series.
    Oral Oncol. 2021;121:105511.
    >> Share

  437. FINEGERSH A, Voora RS, Panuganti B, Faraji F, et al
    Robotic surgery may improve overall survival for T1 and T2 tumors of the hypopharynx: An NCDB cohort study.
    Oral Oncol. 2021;121:105440.
    >> Share

  438. AL MASALMEH N, Kukreja G, Zaiem F, Raza SN, et al
    p16 positive oropharyngeal small cell cancer: A case report.
    Oral Oncol. 2021;121:105391.
    >> Share

  439. HARING CT, Brummel C, Bhambhani C, Jewell B, et al
    Implementation of human papillomavirus circulating tumor DNA to identify recurrence during treatment de-escalation.
    Oral Oncol. 2021;121:105332.
    >> Share

    September 2021
  440. CURY SS, Miranda PM, Marchi FA, Canto LMD, et al
    Germline variants in DNA repair genes are associated with young-onset head and neck cancer.
    Oral Oncol. 2021;122:105545.
    >> Share

  441. WANG BC
    Adjuvant chemotherapy in locoregionally advanced nasopharyngeal carcinoma: Finding the suitable population.
    Oral Oncol. 2021 Sep 28:105544. doi: 10.1016/j.oraloncology.2021.105544.
    >> Share

  442. SARODE SC, Sarode GS, Sengupta N, Ghone U, et al
    Tobacco induced epithelial dysplasia at minor salivary gland excretory duct and oral cancer.
    Oral Oncol. 2021;122:105525.
    >> Share

  443. MILLIET F, Bozec A, Schiappa R, Viotti J, et al
    Metachronous second primary neoplasia in oropharyngeal cancer patients: Impact of tumor HPV status. A GETTEC multicentric study.
    Oral Oncol. 2021;122:105503.
    >> Share

    August 2021
  444. WRIGHT CM, Lee DY, Shimunov D, Carmona R, et al
    Definitive tumor directed therapy confers a survival advantage for metachronous oligometastatic HPV-associated oropharyngeal cancer following trans-oral robotic surgery.
    Oral Oncol. 2021;121:105509.
    >> Share

  445. MCDOWELL L, Corry J
    Regarding "Comparing unilateral vs. bilateral neck management in lateralized oropharyngeal cancer between surgical and radiation oncologists: An international practice pattern survey" - Intra- and inter-specialty variability and the underutilisation o
    Oral Oncol. 2021;119:105248.
    >> Share

  446. CHOI N, Kim Z, Song BH, Park W, et al
    Prediction of risk factors for pharyngo-cutaneous fistula after total laryngectomy using artificial intelligence.
    Oral Oncol. 2021;119:105357.
    >> Share

    July 2021
  447. NAUTA IH, Klausch T, van de Ven PM, Hoebers FJP, et al
    The important role of cisplatin in the treatment of HPV-positive oropharyngeal cancer assessed by real-world data analysis.
    Oral Oncol. 2021;121:105454.
    >> Share

  448. KIM C, Martinez E, Kulich M, Swanson MS, et al
    Surgeon practice patterns in transoral robotic surgery for HPV-related oropharyngeal cancer.
    Oral Oncol. 2021;121:105460.
    >> Share

  449. DA COSTA REAR, da Silva Junior RG, Magalhaes LAN, Mendes JR, et al
    Locally advanced lymphoepithelial carcinoma of the larynx/hypopharynx: A case report.
    Oral Oncol. 2021;118:105373.
    >> Share

  450. TURNER MT, Stokes WA, Stokes CM, Hassid S, et al
    Airway and bleeding complications of transoral robotic supraglottic laryngectomy (TORS-SGL): A systematic review and meta-analysis.
    Oral Oncol. 2021;118:105301.
    >> Share

  451. MCDOWELL L, Gough K, King M, Corry J, et al
    Patient-reported quality of life and symptom burden measures in human papillomavirus associated oropharyngeal cancer - A review of the literature and PRO methodology.
    Oral Oncol. 2021;118:105309.
    >> Share

  452. DHEERAJ K, Kumar R, Pinnaka LB
    6 "I" for endoscopic surgical management of early glottic squamous cell carcinomas.
    Oral Oncol. 2021;118:105308.
    >> Share

    June 2021
  453. DAHLSTROM KR, Anderson KS, Guo M, Kwon MC, et al
    Screening for HPV-related oropharyngeal, anal, and penile cancers in middle-aged men: Initial report from the HOUSTON clinical trial.
    Oral Oncol. 2021;120:105397.
    >> Share

  454. JIANG WN, Olson R
    Transoral surgery may be less cost effective than radiotherapy: In response to: Comparative cost analysis between definitive radiotherapy and transoral surgery for oropharyngeal squamous cell carcinoma: A SEER-medicare analysis.
    Oral Oncol. 2021;117:105178.
    >> Share

  455. PARIKH AS, Kang SY
    Variation in elective treatment of the contralateral neck in oropharyngeal cancer.
    Oral Oncol. 2021;117:105186.
    >> Share

  456. COMBES JD, Voisin N, Perie S, Malard O, et al
    History of tonsillectomy and risk of oropharyngeal cancer.
    Oral Oncol. 2021;117:105302.
    >> Share

  457. JANSEN F, Coupe VMH, Eerenstein SEJ, Cnossen IC, et al
    Cost-utility and cost-effectiveness of a guided self-help head and neck exercise program for patients treated with total laryngectomy: Results of a multi-center randomized controlled trial.
    Oral Oncol. 2021;117:105306.
    >> Share

  458. PATEL MR, Ottenstein L, Ryan M, Farrell A, et al
    TORS elective lingual tonsillectomy has less acute morbidity than therapeutic base of tongue TORS.
    Oral Oncol. 2021;117:105294.
    >> Share

    May 2021
  459. COSTANTINO A, De Virgilio A, Spriano G
    Is the current oropharyngeal cancer T classification adequate in the era of HPV and transoral robotic surgery?
    Oral Oncol. 2021 May 25:105359. doi: 10.1016/j.oraloncology.2021.105359.
    >> Share

  460. ZHOU L
    Concerns about human papillomavirus-associated oropharyngeal cancer detection methods.
    Oral Oncol. 2021;116:105143.
    >> Share

  461. LI R, Wang Q, Yan L, Zhu Y, et al
    Radiotherapy versus partial laryngectomy in the management of early glottic cancer with anterior commissure involvement: A propensity score matched study with 256 patients.
    Oral Oncol. 2021;116:105230.
    >> Share

    April 2021
  462. YVER CM, Shimunov D, Weinstein GS, Rajasekaran K, et al
    Oncologic and survival outcomes for resectable locally-advanced HPV-related oropharyngeal cancer treated with transoral robotic surgery.
    Oral Oncol. 2021;118:105307.
    >> Share

  463. RAJASEKARAN K, Carey RM, Lin X, Seckar TD, et al
    The microbiome of HPV-positive tonsil squamous cell carcinoma and neck metastasis.
    Oral Oncol. 2021;117:105305.
    >> Share

  464. KREINBRINK PJ, Li J, Parajuli S, Wise-Draper TM, et al
    Pre-treatment absolute lymphocyte count predicts for improved survival in human papillomavirus (HPV)-driven oropharyngeal squamous cell carcinoma.
    Oral Oncol. 2021;116:105245.
    >> Share

  465. DHAKAL R, Moeller BJ, Prabhu RS, Frenkel CH, et al
    Pattern of distant metastasis in oropharyngeal carcinoma - Do they differ by HPV status?
    Oral Oncol. 2021 Apr 18:105286. doi: 10.1016/j.oraloncology.2021.105286.
    >> Share

  466. PRICE JM, West CM, Mistry HB, Betts G, et al
    Improved survival prediction for oropharyngeal cancer beyond TNMv8.
    Oral Oncol. 2021;115:105140.
    >> Share

    March 2021
  467. DE ALMEIDA JR, Seungyeon Kim V, O'Sullivan B, Goldstein DP, et al
    Comparing unilateral vs. bilateral neck management in lateralized oropharyngeal cancer between surgical and radiation oncologists: An international practice pattern survey.
    Oral Oncol. 2021;114:105165.
    >> Share

  468. FERRARI M, Migliorati S, Tomasoni M, Crisafulli V, et al
    Sinonasal cancer encroaching the orbit: Ablation or preservation?
    Oral Oncol. 2021;114:105185.
    >> Share

  469. YANG K, Ahn YC, Nam H, Hong SD, et al
    Clinical features of post-radiation nasopharyngeal necrosis and their outcomes following surgical intervention in nasopharyngeal cancer patients.
    Oral Oncol. 2021;114:105180.
    >> Share

  470. HENG Y, Zhang D, Zhou L, Zhang M, et al
    Assessment and treatment strategies for occult contralateral lymph node metastasis in hypopharyngeal squamous cell carcinoma patients with ipsilateral node-positive necks.
    Oral Oncol. 2021;114:105183.
    >> Share

  471. CUI J, Wang D, Nie D, Liu W, et al
    Difference in tumor mutation burden between squamous cell carcinoma in the oral cavity and larynx.
    Oral Oncol. 2021;114:105142.
    >> Share

  472. OPPELT P, Ley JC, Worden F, Palka K, et al
    Palbociclib and cetuximab in cetuximab-resistant human papillomavirus-related oropharynx squamous-cell carcinoma: A multicenter phase 2 trial.
    Oral Oncol. 2021;114:105164.
    >> Share

  473. GOOSMANN M, Chang S, Craig J
    Treating sinonasal crusting and infection after palatal and sinonasal cancer resection with topical antibiotic irrigations.
    Oral Oncol. 2021;114:105077.
    >> Share

    February 2021
  474. FADEN DL, O'Boyle CJ, Lin DT, Deschler DG, et al
    Prospective assessment of multiple HPV-positive oropharyngeal squamous cell carcinomas.
    Oral Oncol. 2021 Feb 15:105212. doi: 10.1016/j.oraloncology.2021.105212.
    >> Share

  475. LEE SJ, Kim YS, Kay CS, Kim M, et al
    The effect of adjuvant chemotherapy and early tumor regression on the outcome of nasopharyngeal cancer patients treated with concurrent chemoradiotherapy.
    Oral Oncol. 2021;113:105130.
    >> Share

  476. CARNEVALE C, Ortiz-Gonzalez I, Ortiz-Gonzalez A, Bodi-Blanes L, et al
    Early T1-T2 stage p16+ oropharyngeal tumours. Role of upfront transoral robotic surgery in de-escalation treatment strategies. A review of the current literature.
    Oral Oncol. 2021;113:105111.
    >> Share

  477. HEFT NEAL ME, Gao RW, Brennan JR, Haring CT, et al
    Functional outcomes and tracheostomy dependence following salvage oropharyngeal surgery.
    Oral Oncol. 2021;113:105034.
    >> Share

    January 2021
  478. PILAR A, Yu E, Su J, O'Sullivan B, et al
    Prognostic value of clinical and radiologic extranodal extension and their role in the 8th edition TNM cN classification for HPV-negative oropharyngeal carcinoma.
    Oral Oncol. 2021;114:105167.
    >> Share

  479. BHATTASALI O, Torres FA, Kang HK, Thompson LDR, et al
    Prognostic impact of retropharyngeal lymphadenopathy in early-stage HPV-associated oropharyngeal cancer: Implications for staging optimization.
    Oral Oncol. 2021;114:105147.
    >> Share

    December 2020
  480. CHRISTOPHERSON KM, Moreno AC, Elgohari B, Gross N, et al
    Outcomes after salvage for HPV-positive recurrent oropharyngeal cancer treated with primary radiation.
    Oral Oncol. 2020;113:105125.
    >> Share

    September 2020
  481. MARTIN M, Sautois B
    Early onset of head and neck squamous-cell carcinoma and fatal toxicity with concurrent chemoradiotherapy in a patient compound heterozygote for FANCA gene.
    Oral Oncol. 2020 Sep 1:104989. doi: 10.1016/j.oraloncology.2020.104989.
    >> Share

    August 2020
  482. CHEN TC, Wu CT, Wang CP, Lou PJ, et al
    The differences of immunologic and TP53 mutant phenotypes between synchronous and metachronous head and neck cancer and esophageal cancer.
    Oral Oncol. 2020;111:104945.
    >> Share

  483. WANG J, Lian CL, Zheng H, Lin LE, et al
    Cognitive dysfunction in patients with nasopharyngeal carcinoma after induction chemotherapy.
    Oral Oncol. 2020;111:104921.
    >> Share

    July 2020
  484. ZENG YY, Xiang ZZ, He T, Liu F, et al
    The comparison of prognostic value of tumour volumetric regression ratio and RECIST 1.1 criteria after induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma.
    Oral Oncol. 2020;111:104924.
    >> Share

  485. WANG Q, Xu G, Xia Y, Zuo J, et al
    Comparison of induction chemotherapy plus concurrent chemoradiotherapy and induction chemotherapy plus radiotherapy in locally advanced nasopharyngeal carcinoma.
    Oral Oncol. 2020;111:104925.
    >> Share

  486. LI W, Lu H, Liu J, Liu Q, et al
    A novel nomogram to predict survival in patients with recurrent nasopharyngeal carcinoma after salvage endoscopic surgery.
    Oral Oncol. 2020;111:104922.
    >> Share

  487. HSU AC, Kokot NC, Eisenberg BL, Thomas JS, et al
    Complete response with talimogene laherparepvec in recurrent melanoma of the ear: A case report.
    Oral Oncol. 2020 Jul 11:104899. doi: 10.1016/j.oraloncology.2020.104899.
    >> Share

  488. MATOS LL, Pinheiro RA, Kowalski LP
    Depth of invasion applied to oropharynx does not improve prognosis discrimination according to AJCC stage groups for oral cancer.
    Oral Oncol. 2020 Jul 9:104890. doi: 10.1016/j.oraloncology.2020.104890.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016